# 7 APPENDICES

**Page range:** 66â€“201

```text
7.
APPENDICES

67
Drug Safety Report No: 1132062
Appendix 1
Clinical Trial Outputs

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3301/004 - 73/F/Asian
    Investigations
      Alanine aminotransferase increased             14SEP2022       22        43       No         No       MOD            Yes         3            2
      Aspartate aminotransferase increased           14SEP2022       22       134       No         No       MOD            Yes         3            2
    Infections and infestations
      Nasopharyngitis                                14SEP2022       59         6       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       14SEP2022      100         7       No         No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           14SEP2022      198                 No         No       MILD           Yes         2            2
    Infections and infestations
      Nasopharyngitis                                14SEP2022      297        67       No         No       MILD           No          3            2

  3301/006 - 57/M/Asian
    Infections and infestations
      Urinary tract infection                        24MAY2023      267         8       No         No       MOD            No          3            2

  3301/008 - 67/F/Asian
    Infections and infestations
      Paronychia                                     17OCT2023       22                 No         No       MILD           Yes         2            2
    Infections and infestations
      Pneumonia cytomegaloviral                      17OCT2023       85        21       No         Yes      SEV            Yes         3            4

  3302/003 - 61/F/Asian
    Investigations
      Alanine aminotransferase increased             27APR2021       15         8       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           27APR2021       15       143       No         No       MILD           Yes         3            2
    Investigations
      Lymphocyte count decreased                     27APR2021      127        24       No         No       MILD           Yes         3            2
    Investigations
      Lymphocyte count decreased                     27APR2021      157        22       No         No       MILD           Yes         3            2

  3302/004 - 71/M/Asian
    Investigations
      Blood thyroid stimulating hormone increased    27APR2021       22         8       No         No       MILD           No          3            2
      Platelet count decreased                       27APR2021       22       107       No         No       SEV            Yes         3            3
    Investigations
      Aspartate aminotransferase increased           27APR2021       86         8       No         No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 1 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3302/004 - 71/M/Asian
    Investigations
      Aspartate aminotransferase increased           27APR2021      189         8       No         No       MILD           Yes         3            2
    Infections and infestations
      Pleural infection                              27APR2021      204        73       No         Yes      SEV            No          3            4
    Investigations
      Platelet count decreased                       27APR2021      204        21       No         No       MOD            No          3            2
    Infections and infestations
      Device related infection                       27APR2021      214        16       No         Yes      SEV            No          3            2
    Investigations
      Blood creatinine increased                     27APR2021      233         1       No         No       MOD            No          3            2
    Investigations
      Blood bicarbonate decreased                    27APR2021      252                 No         No       MOD            No          2            6
    Investigations
      Alanine aminotransferase increased             27APR2021      262                 No         No       MILD           No          2            6
      Aspartate aminotransferase increased           27APR2021      262         2       No         No       MILD           No          3            6
      Neutrophil count decreased                     27APR2021      262                 No         No       LT             No          2            6
      Platelet count decreased                       27APR2021      262                 No         No       LT             No          2            6

  3302/005 - 74/M/Asian
    Investigations
      Aspartate aminotransferase increased           10AUG2021       22        60       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             10AUG2021       64        14       No         No       MILD           Yes         3            2
    Infections and infestations
      Pneumonia                                      10AUG2021       65                 No         Yes      SEV            No          2            5
    Investigations
      Alanine aminotransferase increased             10AUG2021       79         6       No         No       MILD           No          3            2
    Investigations
      Blood thyroid stimulating hormone decreased    10AUG2021      106                 No         No       MILD           No          2            6

  3302/006 - 51/F/Asian
    Investigations
      Alanine aminotransferase increased             10AUG2021      147        23       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           10AUG2021      147        23       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           10AUG2021      234        82       No         No       MILD           Yes         3            2
      Blood cholesterol increased                    10AUG2021      234        19       No         No       MILD           No          3            2
      Blood lactate dehydrogenase increased          10AUG2021      234                 No         No       MILD           No          2            2
    Investigations
      Aspartate aminotransferase increased           10AUG2021      424        39       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           10AUG2021      546        45       No         No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 2 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3302/006 - 51/F/Asian
    Investigations
      Aspartate aminotransferase increased           10AUG2021      674        45       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           10AUG2021      842                 No         No       MILD           Yes         2            2

  3302/007 - 52/F/Asian
    Investigations
      Alanine aminotransferase increased             23NOV2021       22        21       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           23NOV2021       22        21       No         No       MOD            Yes         3            2
    Investigations
      Lymphocyte count decreased                     23NOV2021       44        21       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        23NOV2021       85        11       No         No       MOD            Yes         3            2
    Investigations
      Aspartate aminotransferase increased           23NOV2021      127        42       No         No       MILD           Yes         3            2
    Infections and infestations
      Pneumocystis jirovecii pneumonia               23NOV2021      161        33       No         Yes      SEV            No          4            4
      Pneumonia cytomegaloviral                      23NOV2021      161                 No         Yes      SEV            No          2            5
    Investigations
      Aspartate aminotransferase increased           23NOV2021      210         2       No         No       MILD           Yes         3            2

  3302/012 - 57/M/Asian
    Investigations
      Alanine aminotransferase increased             13JUL2023       22        43       No         No       MILD           Yes         3            2
      Blood creatinine increased                     13JUL2023       22                 No         No       MILD           No          2            2
    Infections and infestations
      Pneumonia                                      13JUL2023       58        14       No         Yes      DEATH          No          1            5

  3302/013 - 67/F/Asian
    Investigations
      Alanine aminotransferase increased             05DEC2023       22        43       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           05DEC2023       22        53       No         No       MILD           Yes         3            2
    Infections and infestations
      Pneumonia                                      05DEC2023       67        11       No         Yes      SEV            No          3            4
      Pyelonephritis acute                           05DEC2023       67         4       No         Yes      SEV            No          3            4

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 3 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3303/001 - 60/M/Asian
    Infections and infestations
      Pneumonia                                      17MAR2021      361        10       No         Yes      MOD            No          3            4
    Investigations
      Neutrophil count decreased                     17MAR2021      840         7       No         No       SEV            Yes         3            4
    Investigations
      Neutrophil count decreased                     17MAR2021      847                 No         No       MOD            Yes         2            3

  4101/001 - 64/M/White
    Investigations
      Neutrophil count decreased                     09NOV2020       22        99       No         No       SEV            Yes         3            3
    Investigations
      Blood creatinine increased                     09NOV2020       64         8       No         No       MOD            Yes         3            2
    Investigations
      Neutrophil count decreased                     09NOV2020      162        43       No         No       SEV            Yes         3            3
    Investigations
      Platelet count decreased                       09NOV2020      183        22       No         No       MOD            Yes         3            2
    Investigations
      Blood creatinine increased                     09NOV2020      246        64       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       09NOV2020      653        58       No         No       MOD            No          3            2
    Infections and infestations
      Upper respiratory tract infection              09NOV2020     1177         6       No         No       MOD            No          3            2

  4201/002 - 76/F/Unknown
    Infections and infestations
      Urinary tract infection                        03MAY2023       13         4       No         No       MOD            No          3            2
    Infections and infestations
      Pyelonephritis                                 03MAY2023       17        15       No         Yes      SEV            No          3            4
    Infections and infestations
      Pneumonia                                      03MAY2023       30        10       No         Yes      DEATH          No          1            2

  4201/003 - 56/M/Unknown
    Infections and infestations
      Lower respiratory tract infection              07JUL2023       46        18       No         No       MOD            No          3            2
    Investigations
      Aspartate aminotransferase increased           07JUL2023       46        43       No         No       MILD           No          3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 4 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4202/001 - 77/F/White
    Investigations
      Neutrophil count decreased                     12MAY2021       20        10       No         No       SEV            Yes         3            3
    Infections and infestations
      Staphylococcal sepsis                          12MAY2021      290        10       No         Yes      SEV            No          3            2

  4205/002 - 45/F/NOT REPORTED
    Infections and infestations
      Tongue fungal infection                        03AUG2022      106                 No         No       MOD            No          2            2
    Infections and infestations
      Gastroenteritis                                03AUG2022      190         1       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             03AUG2022      398        23       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           03AUG2022      398        23       No         No       MILD           Yes         3            2

  4205/004 - 78/F/White
    Infections and infestations
      Tongue fungal infection                        11APR2023       22        45       No         No       MILD           Yes         3            2
    Investigations
      Weight increased                               11APR2023       66                 No         No       MILD           Yes         2            2
    Investigations
      Blood creatine phosphokinase increased         11APR2023      148        21       No         No       MILD           Yes         3            2
    Infections and infestations
      Viral infection                                11APR2023      217         3       No         No       MILD           No          3            2
    Infections and infestations
      Gastroenteritis                                11APR2023      235*       31**     No         No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         11APR2023      274        22       No         No       MILD           Yes         3            2
    Infections and infestations
      Localised infection                            11APR2023      359                 No         No       MILD           No          2            2
    Investigations
      Blood creatine phosphokinase increased         11APR2023      359                 No         No       MILD           Yes         2            2

  4206/001 - 71/F/NOT REPORTED
    Investigations
      Alanine aminotransferase increased             29JUL2020       16        46       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           29JUL2020       16        28       No         No       MILD           Yes         3            2
    Infections and infestations
      Oral fungal infection                          29JUL2020       48        39       No         No       MILD           No          3            2
      Pyelonephritis                                 29JUL2020       48        30       No         Yes      SEV            Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 5 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4206/001 - 71/F/NOT REPORTED
    Investigations
      Alanine aminotransferase increased             29JUL2020       84        43       No         No       MILD           Yes         3            2
    Infections and infestations
      Pyelonephritis                                 29JUL2020       96       180       No         Yes      SEV            Yes         4            3
    Investigations
      Alanine aminotransferase increased             29JUL2020      189        44       No         No       MILD           Yes         3            2
    Infections and infestations
      Urinary tract infection                        29JUL2020      332        86       No         No       MOD            Yes         3            3
    Infections and infestations
      Urinary tract infection                        29JUL2020      457        12       No         No       MILD           Yes         3            2
    Infections and infestations
      Urinary tract infection                        29JUL2020      580        19       No         No       MILD           Yes         3            2
    Infections and infestations
      Urinary tract infection                        29JUL2020      603        10       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        29JUL2020      631       678       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             29JUL2020      798        40       No         No       MILD           No          3            2
      Gamma-glutamyltransferase increased            29JUL2020      798        40       No         No       MILD           No          3            2

  4208/002 - 76/M/NOT REPORTED
    Investigations
      Blood creatine phosphokinase increased         06MAY2022      106                 No         No       SEV            Yes         5            3
    Investigations
      Weight decreased                               06MAY2022      149                 No         No       MILD           No          2            2

  4208/004 - 73/F/Other
    Infections and infestations
      Oesophageal infection                          08NOV2022       52        16       No         No       SEV            Yes         3            2
      Oral fungal infection                          08NOV2022       52        16       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        08NOV2022       55         8       No         No       MILD           No          3            2
    Infections and infestations
      Pneumonia                                      08NOV2022       86        16       No         Yes      MOD            No          3            4
    Investigations
      Blood creatinine increased                     08NOV2022      193                 No         No       MOD            No          2            4
    Infections and infestations
      Vascular device infection                      08NOV2022      284         8       No         No       MOD            No          3            4

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 6 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4209/001 - 52/F/White
    Investigations
      Alanine aminotransferase increased             04SEP2021       18                 No         No       MILD           Yes         2            2
      Aspartate aminotransferase increased           04SEP2021       18        22       No         No       MILD           Yes         3            2
    Infections and infestations
      Fungal infection                               04SEP2021       97        55       No         No       MILD           No          3            2
    Investigations
      Oxygen saturation decreased                    04SEP2021      104         2       No         No       MOD            No          3            2
    Infections and infestations
      Pneumonia                                      04SEP2021      105         6       No         No       MOD            No          3            4

  4210/001 - 67/M/Unknown
    Investigations
      Blood creatinine increased                     10JAN2024       22                 No         No       MOD            Yes         5            2

  4307/001 - 58/M/White
    Investigations
      Neutrophil count decreased                     30DEC2020        8        56       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               30DEC2020       22        21       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               30DEC2020       43        21       No         No       MILD           Yes         3            2
    Investigations
      White blood cell count decreased               30DEC2020      106        21       No         No       MILD           Yes         3            2
    Investigations
      White blood cell count decreased               30DEC2020      148        58       No         No       MILD           Yes         3            2
    Infections and infestations
      Urinary tract infection                        30DEC2020      199        28       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       30DEC2020      311        26       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               30DEC2020      581        45       No         No       MILD           Yes         3            2

  4307/003 - 40/F/White
    Infections and infestations
      Bronchitis                                     28APR2021       80        32       No         No       MOD            Yes         3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 7 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4307/004 - 59/F/White
    Investigations
      Neutrophil count decreased                     21APR2021       21        43       No         No       SEV            Yes         3            3
      Platelet count decreased                       21APR2021       21        43       No         No       MILD           Yes         3            2
    Investigations
      White blood cell count decreased               21APR2021       35        29       No         No       SEV            Yes         3            2
    Investigations
      Neutrophil count decreased                     21APR2021       85        41       No         No       MOD            Yes         3            2
      White blood cell count decreased               21APR2021       85        41       No         No       MOD            Yes         3            2
    Infections and infestations
      Fungal infection                               21APR2021      126        28       No         No       MILD           No          3            2
    Investigations
      Neutrophil count decreased                     21APR2021      126        28       No         No       MILD           Yes         3            2
      White blood cell count decreased               21APR2021      126        49       No         No       MILD           Yes         3            2
    Infections and infestations
      Urinary tract infection                        21APR2021      153        17       No         No       MOD            Yes         3            2
    Investigations
      Neutrophil count decreased                     21APR2021      154        22       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               21APR2021      196        21       No         No       MILD           Yes         3            2
    Infections and infestations
      Nasopharyngitis                                21APR2021      212        26       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               21APR2021      259        63       No         No       MOD            Yes         3            2
    Investigations
      Neutrophil count decreased                     21APR2021      301        21       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        21APR2021      305         9       No         No       MOD            No          3            2
    Infections and infestations
      Cystitis                                       21APR2021      314         8       No         No       MILD           No          3            2
    Investigations
      Neutrophil count decreased                     21APR2021      343        64       No         No       MOD            Yes         3            2
      White blood cell count decreased               21APR2021      343       169       No         No       MOD            Yes         3            2
    Infections and infestations
      Respiratory tract infection                    21APR2021      444        26       No         No       MOD            Yes         3            2
      Urinary tract infection                        21APR2021      444        26       No         No       MOD            Yes         3            2
    Infections and infestations
      Paronychia                                     21APR2021      470       170       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                21APR2021      626        56       No         No       MILD           No          3            2
    Infections and infestations
      Pneumonia                                      21APR2021      825        13       No         Yes      SEV            Yes         3            6

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 8 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4307/005 - 59/M/White
    Investigations
      White blood cell count decreased               07JUL2021       43        23       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               07JUL2021       84        42       No         No       MILD           Yes         3            2
    Infections and infestations
      Nasopharyngitis                                07JUL2021      116        12       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               07JUL2021      169        20       No         No       MILD           Yes         3            2
    Infections and infestations
      Nasopharyngitis                                07JUL2021      175        15       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               07JUL2021      210        42       No         No       MILD           Yes         3            2
    Investigations
      Neutrophil count decreased                     07JUL2021      274        21       No         No       MOD            Yes         3            2
      White blood cell count decreased               07JUL2021      274        21       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               07JUL2021      463        62       No         No       MOD            Yes         3            2
    Investigations
      Neutrophil count decreased                     07JUL2021      505        21       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               07JUL2021      547                 No         No       MOD            Yes         2            2
    Investigations
      Neutrophil count decreased                     07JUL2021      631        51       No         No       MILD           Yes         3            2
    Infections and infestations
      Nasopharyngitis                                07JUL2021      682        21       No         No       MILD           No          3            2

  4312/001 - 77/M/White
    Investigations
      White blood cell count decreased               09OCT2020       43                 No         No       SEV            Yes         2            2
    Infections and infestations
      Herpes zoster                                  09OCT2020      442        12       No         No       MOD            No          3            2

  4402/003 - 56/F/White
    Infections and infestations
      Oral candidiasis                               14DEC2022       33        27       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       14DEC2022       44         8       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             14DEC2022      169        43       No         No       MILD           No          3            2
      Aspartate aminotransferase increased           14DEC2022      169        43       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                         Page 9 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4403/003 - 61/M/White
    Investigations
      Blood bicarbonate decreased                    28JUL2023       41        27       No         No       MILD           Yes         3            2
    Investigations
      Amylase increased                              28JUL2023       55        20       No         No       MOD            No          3            2
      Blood phosphorus decreased                     28JUL2023       55        20       No         No       MILD           No          3            2
    Investigations
      Amylase increased                              28JUL2023       61        14       No         No       MOD            No          3            2
      Lipase increased                               28JUL2023       61        56       No         No       MOD            No          3            2
    Investigations
      Amylase increased                              28JUL2023       95                 No         No       MOD            No          5            2
                                                     28JUL2023       95                 No         No       MOD            No          5            2
    Investigations
      Gamma-glutamyltransferase increased            28JUL2023      116                 No         No       MILD           No          5            2
      Lymphocyte count decreased                     28JUL2023      116                 No         No       MOD            No          5            2
      Protein total decreased                        28JUL2023      116                 No         No       MILD           No          5            2

  4404/003 - 57/M/White
    Investigations
      Platelet count decreased                       23DEC2020       23        22       No         No       MOD            Yes         3            2
    Infections and infestations
      Nasopharyngitis                                23DEC2020      325         4       No         No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           23DEC2020      443                 No         No       MILD           No          5            2
    Infections and infestations
      Gastroenteritis viral                          23DEC2020      633         5       No         No       MOD            No          3            4
    Infections and infestations
      COVID-19                                       23DEC2020      888         6       No         No       MILD           No          3            4
      Herpes zoster                                  23DEC2020      888         9       No         Yes      SEV            No          3            4
      Spontaneous bacterial peritonitis              23DEC2020      888         9       No         Yes      SEV            No          3            4
    Infections and infestations
      Gastroenteritis                                23DEC2020     1149         9       No         Yes      MOD            No          3            4
    Infections and infestations
      Gastroenteritis                                23DEC2020     1169         8       No         Yes      MOD            No          3            4

  4404/004 - 57/M/White
    Investigations
      Blood alkaline phosphatase increased           05JAN2021        1                 No         No       MILD           No          2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 10 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4404/004 - 57/M/White
    Infections and infestations
      Cystitis                                       05JAN2021       22                 No         No       MOD            No          5            2

  4404/005 - 53/M/White
    Infections and infestations
      Device related infection                       14APR2021       20        12       No         Yes      LT             No          3            4
    Infections and infestations
      Cystitis                                       14APR2021      147         9       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             14APR2021      191        28       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           14APR2021      191        28       No         No       MILD           Yes         3            2
    Infections and infestations
      Escherichia urinary tract infection            14APR2021      314         9       No         No       MILD           No          3            2
    Infections and infestations
      Cystitis                                       14APR2021      338         7       No         No       MOD            No          3            4
    Infections and infestations
      Herpes zoster                                  14APR2021      386                 No         No       MOD            No          5            5
    Investigations
      Platelet count decreased                       14APR2021      434                 No         No       MILD           Yes         5            2
    Investigations
      SARS-CoV-2 test positive                       14APR2021      472                 No         No       MILD           No          5            6

  4404/009 - 68/M/White
    Infections and infestations
      COVID-19                                       02DEC2021       48        25       No         No       MILD           No          3            4
    Investigations
      Transaminases abnormal                         02DEC2021      107                 No         No       MILD           Yes         5            2
    Infections and infestations
      Urinary tract infection                        02DEC2021      392         2       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     02DEC2021      400                 No         No       MILD           Yes         5            2

  4404/011 - 71/M/White
    Infections and infestations
      Paronychia                                     19AUG2022       84                 No         No       MILD           Yes         5            2
    Infections and infestations
      Infection                                      19AUG2022      146        17       No         No       MOD            No          3            4
    Investigations
      Aspartate aminotransferase increased           19AUG2022      273                 No         No       MILD           No          5            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 11 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4404/011 - 71/M/White
    Infections and infestations
      Q fever                                        19AUG2022      406        30       No         Yes      SEV            No          3            4
    Infections and infestations
      Pneumonia                                      19AUG2022      636                 No         Yes      SEV            No          2            4

  4404/012 - 46/M/White
    Investigations
      Blood creatinine increased                     21SEP2022       23                 No         No       MILD           No          5            2
      Transaminases increased                        21SEP2022       23       293       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             21SEP2022       86                 No         No       MILD           Yes         5            2
      Aspartate aminotransferase increased           21SEP2022       86                 No         No       MILD           Yes         5            2
    Infections and infestations
      Pneumonia                                      21SEP2022      154         9       No         No       MOD            Yes         3            4
    Infections and infestations
      Pneumonia                                      21SEP2022      210                 No         No       MILD           Yes         5            2
    Infections and infestations
      Pneumonia                                      21SEP2022      456        20       No         Yes      MOD            No          3            4
    Investigations
      Transaminases increased                        21SEP2022      524        85       No         No       MILD           Yes         3            4

  4406/001 - 60/M/White
    Investigations
      Blood creatine phosphokinase increased         28APR2021      307        53       No         No       SEV            No          3            2
    Infections and infestations
      Urinary tract infection                        28APR2021      636        16       No         No       MILD           No          3            2

  4406/003 - 53/M/White
    Investigations
      Aspartate aminotransferase increased           30MAR2022       23                 No         No       MILD           Yes         2            2
      White blood cell count decreased               30MAR2022       23                 No         No       MILD           Yes         2            2
    Investigations
      Blood creatinine increased                     30MAR2022      148        22       No         No       MILD           No          3            2
    Infections and infestations
      Urinary tract infection                        30MAR2022      568                 No         Yes      SEV            No          5            2
    Infections and infestations
      Nail infection                                 30MAR2022      583        15       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       30MAR2022      644         7       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 12 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4407/001 - 58/M/White
    Investigations
      Blood cholesterol increased                    11MAR2021       14                 No         No       MOD            No          5            2
      Blood creatine phosphokinase increased         11MAR2021       14       220       No         No       MOD            Yes         3            2
    Investigations
      White blood cell count decreased               11MAR2021       22       131       No         No       MOD            Yes         3            2
    Infections and infestations
      Pharyngitis                                    11MAR2021       57         5       No         Yes      MOD            No          3            2
    Infections and infestations
      Herpes zoster                                  11MAR2021      756         7       No         No       MOD            No          3            4

  4407/002 - 64/M/White
    Investigations
      Alanine aminotransferase increased             07JUN2021       89        22       No         No       SEV            Yes         3            4
      Aspartate aminotransferase increased           07JUN2021       89         6       No         No       MOD            Yes         3            2
    Infections and infestations
      Pustule                                        07JUN2021      297        29       No         No       MOD            Yes         3            2

  4407/003 - 70/F/White
    Infections and infestations
      Cytomegalovirus infection                      22OCT2021       86        10       No         No       MILD           No          3            2

  4407/004 - 55/F/White
    Infections and infestations
      Fungal infection                               14JUN2022      149         8       No         No       MILD           No          3            2

  4408/002 - 57/M/White
    Infections and infestations
      Oropharyngeal candidiasis                      02MAY2023      263         8       No         No       MILD           Yes         3            4

  4410/001 - 41/F/White
    Investigations
      Blood creatinine increased                     04MAR2021      190       189       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 13 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4410/001 - 41/F/White
    Investigations
      Haemoglobin decreased                          04MAR2021      232       147       No         No       MILD           Yes         3            2

  4410/003 - 63/M/White
    Infections and infestations
      COVID-19                                       25MAY2021      233        23       No         No       MILD           No          3            4
    Investigations
      Blood bilirubin increased                      25MAY2021      302        63       No         No       MILD           Yes         3            2
    Investigations
      Weight increased                               25MAY2021      659                 No         No       MILD           No          2            2
    Infections and infestations
      Pharyngitis                                    25MAY2021      683         4       No         No       MILD           No          3            2
    Infections and infestations
      Erysipelas                                     25MAY2021      769        57       No         No       MOD            No          3            2
    Investigations
      Blood creatinine increased                     25MAY2021      890                 No         No       MILD           No          2            2

  4410/004 - 67/M/White
    Investigations
      Alanine aminotransferase increased             23JUL2021       46       147       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           23JUL2021       46       147       No         No       MILD           Yes         3            2
    Infections and infestations
      Pneumonia                                      23JUL2021      459       352       No         Yes      MOD            No          3            4
    Infections and infestations
      Urinary tract infection                        23JUL2021      735                 No         No       MILD           No          2            4
    Investigations
      Neutrophil count decreased                     23JUL2021      980                 No         No       MILD           Yes         2            2

  4410/007 - 62/M/White
    Investigations
      Aspartate aminotransferase increased           23SEP2022       22        21       No         No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           23SEP2022      313        22       No         No       MILD           Yes         3            2
      Blood glucose increased                        23SEP2022      313                 No         No       MILD           No          2            2
    Infections and infestations
      COVID-19                                       23SEP2022      346         7       No         No       MILD           No          3            4
    Investigations
      Haemoglobin decreased                          23SEP2022      355       106       No         No       MILD           Yes         3            2
    Investigations
      Haemoglobin decreased                          23SEP2022      589                 No         No       MILD           Yes         2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 14 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4410/008 - 65/M/White
    Infections and infestations
      COVID-19 pneumonia                             06MAR2023       26        37       No         Yes      SEV            No          3            4
      Pneumonia legionella                           06MAR2023       26        37       No         Yes      SEV            No          4            4
    Infections and infestations
      Pneumonia                                      06MAR2023       58                 No         Yes      SEV            No          2            4
    Investigations
      Blood creatinine increased                     06MAR2023      148                 No         No       MILD           No          2            2
    Infections and infestations
      Severe acute respiratory syndrome              06MAR2023      238         9       No         No       MILD           No          3            4

  4411/001 - 65/M/White
    Investigations
      Alanine aminotransferase increased             03APR2023      234        50       No         No       MILD           No          3            2
      Aspartate aminotransferase increased           03APR2023      234        50       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     03APR2023      381                 No         No       MILD           No          5            2

  4412/003 - 82/F/White
    Infections and infestations
      Pneumonia                                      05AUG2021       90        35       No         No       MILD           Yes         3            3
    Investigations
      Transaminases increased                        05AUG2021      713        66       No         No       MILD           No          3            2
    Investigations
      Ejection fraction decreased                    05AUG2021      785                 No         No       MOD            No          2            4

  4412/004 - 54/F/White
    Investigations
      Escherichia test positive                      29NOV2022       32        21       No         No       MOD            No          3            4
    Investigations
      Alanine aminotransferase increased             29NOV2022       37         9       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             29NOV2022       73                 No         No       MILD           Yes         2            2
      Aspartate aminotransferase increased           29NOV2022       73                 No         No       MILD           Yes         2            2
    Infections and infestations
      Urinary tract infection                        29NOV2022      144        17       No         No       MOD            Yes         3            4
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 15 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4412/005 - 62/M/White
    Investigations
      Alanine aminotransferase increased             02FEB2023       22       153       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           02FEB2023       22       153       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             02FEB2023      204        21       No         No       MOD            Yes         3            2
      Aspartate aminotransferase increased           02FEB2023      204        21       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             02FEB2023      225        36       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           02FEB2023      225        36       No         No       MILD           Yes         3            2
    Investigations
      Electrocardiogram QT prolonged                 02FEB2023      246        26       No         No       MOD            No          3            4
    Infections and infestations
      COVID-19                                       02FEB2023      275        12       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             02FEB2023      294                 No         No       MOD            Yes         2            2
      Aspartate aminotransferase increased           02FEB2023      294                 No         No       MILD           Yes         2            2
    Investigations
      Blood creatinine increased                     02FEB2023      426                 No         No       MILD           No          2            2

  4412/008 - 56/F/White
    Investigations
      Alanine aminotransferase increased             08SEP2023       22        41       No         No       MILD           No          3            2
      Aspartate aminotransferase increased           08SEP2023       22        41       No         No       MILD           No          3            2
      Blood alkaline phosphatase increased           08SEP2023       22        42       No         No       MILD           No          3            2
    Investigations
      Blood lactate dehydrogenase increased          08SEP2023       43        32       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             08SEP2023       63        19       No         No       MOD            Yes         3            4
      Aspartate aminotransferase increased           08SEP2023       63        19       No         No       MOD            Yes         3            4
    Investigations
      Neutrophil count decreased                     08SEP2023       69                 No         No       MOD            No          2            2
    Investigations
      Alanine aminotransferase increased             08SEP2023       81                 No         No       SEV            Yes         2            2
      Aspartate aminotransferase increased           08SEP2023       81        99       No         No       MOD            Yes         3            2
    Investigations
      Aspartate aminotransferase increased           08SEP2023      200                 No         No       MILD           Yes         2            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 16 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4412/009 - 46/M/White
    Investigations
      Alanine aminotransferase increased             06OCT2023       42       110       No         No       MILD           No          3            2
      Aspartate aminotransferase increased           06OCT2023       42       117       No         No       MILD           No          3            2
    Investigations
      Blood lactate dehydrogenase increased          06OCT2023       63        65       No         No       MILD           No          3            2
    Investigations
      Streptococcus test positive                    06OCT2023       77         7       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     06OCT2023      127        40       No         No       MILD           No          3            2
    Infections and infestations
      Pneumonia                                      06OCT2023      167                 No         No       MOD            No          2            4
    Investigations
      Blood lactate dehydrogenase increased          06OCT2023      225        43       No         No       MILD           Yes         3            2

  4415/003 - 36/M/White
    Infections and infestations
      COVID-19                                       04AUG2023       80         8       No         No       MOD            No          3            2
    Infections and infestations
      Streptococcal infection                        04AUG2023      188         8       No         No       MILD           No          3            2
    Infections and infestations
      Cystitis                                       04AUG2023      213         2       No         No       MILD           No          3            2

  4505/001 - 50/F/White
    Investigations
      Blood alkaline phosphatase increased           28JUL2021       22        22       No         No       MILD           No          3            2
      Neutrophil count decreased                     28JUL2021       22        38       No         No       SEV            Yes         3            3
    Investigations
      Aspartate aminotransferase increased           28JUL2021       43        15       No         No       MILD           Yes         3            2
      Blood creatinine increased                     28JUL2021       43         8       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           28JUL2021       79        63       No         No       MILD           Yes         3            2
      Neutrophil count decreased                     28JUL2021       79        21       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             28JUL2021      120        22       No         No       MILD           No          3            2
      Neutrophil count decreased                     28JUL2021      120        22       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             28JUL2021      162        43       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           28JUL2021      162       190       No         No       MILD           Yes         3            2
    Infections and infestations
      Upper respiratory tract infection              28JUL2021      187        24       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 17 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4505/001 - 50/F/White
    Investigations
      Neutrophil count decreased                     28JUL2021      204        22       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             28JUL2021      225        85       No         No       MILD           Yes         3            2
    Investigations
      Neutrophil count decreased                     28JUL2021      246        43       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             28JUL2021      330        22       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       28JUL2021      334        10       No         No       MILD           No          3            2

  4505/003 - 59/M/White
    Investigations
      Alanine aminotransferase increased             14SEP2022       21        70       No         No       MILD           Yes         3            2
    Investigations
      Blood creatine phosphokinase increased         14SEP2022       42        49       No         No       SEV            Yes         3            3
    Investigations
      Amylase increased                              14SEP2022       83         8       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           14SEP2022       83         8       No         No       MILD           Yes         3            2
    Infections and infestations
      Nasopharyngitis                                14SEP2022      131        45       No         No       MILD           No          3            2
    Investigations
      Blood creatine phosphokinase increased         14SEP2022      133        57       No         No       SEV            Yes         3            3
    Investigations
      Alanine aminotransferase increased             14SEP2022      154        36       No         No       MILD           Yes         3            2
      Amylase increased                              14SEP2022      154        22       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           14SEP2022      175        15       No         No       MILD           Yes         3            2
    Investigations
      Amylase increased                              14SEP2022      182         8       No         No       MILD           Yes         3            2
    Investigations
      Amylase increased                              14SEP2022      196        22       No         No       MILD           Yes         3            2
      Lipase increased                               14SEP2022      196        32       No         No       MILD           Yes         3            2
    Investigations
      Blood creatine phosphokinase increased         14SEP2022      217                 No         No       MILD           Yes         2            2
    Investigations
      Alanine aminotransferase increased             14SEP2022      259        22       No         No       MILD           Yes         3            2

  4507/003 - 59/F/White
    Investigations
      Amylase increased                              30NOV2022      356        22       No         No       MOD            No          3            2
      Lipase increased                               30NOV2022      356                 No         No       SEV            No          2            4
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 18 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4507/003 - 59/F/White
    Investigations
      Amylase increased                              30NOV2022      400                 No         No       MILD           No          2            2

  4508/002 - 79/F/White
    Infections and infestations
      Infection                                      24NOV2022       89                 No         Yes      SEV            No          5            2

  4508/003 - 72/M/White
    Investigations
      Blood creatinine increased                     13JAN2023       21       105       No         No       MILD           No          3            2
      Platelet count decreased                       13JAN2023       21       102       No         No       SEV            No          3            2
    Investigations
      Aspartate aminotransferase increased           13JAN2023       35        91       No         No       MILD           Yes         3            2
    Investigations
      Bilirubin conjugated increased                 13JAN2023       42        84       No         No       MILD           No          3            2
    Investigations
      Blood bilirubin increased                      13JAN2023       62         8       No         No       MOD            No          3            2
    Investigations
      Weight decreased                               13JAN2023       63        64       No         No       MOD            No          3            2
    Infections and infestations
      Sepsis                                         13JAN2023       78        46       No         Yes      LT             No          3            4
    Infections and infestations
      Pseudomembranous colitis                       13JAN2023      100        24       No         Yes      SEV            No          3            4
    Infections and infestations
      Sepsis                                         13JAN2023      155         1       No         Yes      DEATH          No          1            5

  4511/002 - 45/F/White
    Infections and infestations
      Influenza                                      16DEC2022       23        21       No         No       MILD           No          3            2
    Infections and infestations
      Pharyngitis                                    16DEC2022      155        78       No         No       MOD            No          3            2

  4511/004 - 44/M/White
    Investigations
      Blood creatine phosphokinase increased         23NOV2023       22                 No         No       MOD            Yes         2            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 19 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4517/001 - 58/M/White
    Investigations
      Blood creatinine increased                     22OCT2020       22        63       No         No       MILD           No          3            2
    Infections and infestations
      Pneumocystis jirovecii pneumonia               22OCT2020       46        13       No         Yes      MOD            No          3            4
    Investigations
      Blood lactate dehydrogenase increased          22OCT2020      146        63       No         No       MILD           No          3            2
    Infections and infestations
      Atypical pneumonia                             22OCT2020      147                 No         Yes      MOD            No          2            2
    Infections and infestations
      Bronchopulmonary aspergillosis                 22OCT2020      148        61       No         No       SEV            No          3            2
    Infections and infestations
      Atypical pneumonia                             22OCT2020      152        11       No         Yes      MOD            No          4            4
    Investigations
      Alanine aminotransferase increased             22OCT2020      176        33       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     22OCT2020      372        72       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       22OCT2020      693        24       No         No       MILD           No          3            2
    Infections and infestations
      Gastroenteritis                                22OCT2020      864        14       No         No       MILD           No          3            2
    Infections and infestations
      Urinary tract infection                        22OCT2020     1001         6       No         Yes      SEV            No          3            2
    Investigations
      Nitrite urine present                          22OCT2020     1121        22       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                22OCT2020     1171         4       No         No       MILD           No          3            2

  4517/003 - 76/F/White
    Infections and infestations
      Rhinitis                                       02JUN2022        8                 No         No       MILD           No          5            2
    Infections and infestations
      COVID-19                                       02JUN2022       33        18       No         No       MILD           No          3            4
    Infections and infestations
      Herpes zoster                                  02JUN2022      183        12       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                02JUN2022      201        45       No         No       MOD            No          3            3

  4518/001 - 63/F/White
    Investigations
      Alanine aminotransferase increased             01AUG2023       22        85       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           01AUG2023       22                 No         No       MILD           Yes         2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 20 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4518/001 - 63/F/White
    Investigations
      Alanine aminotransferase increased             01AUG2023      127        23       No         No       MILD           Yes         3            2

  4601/001 - 61/F/White
    Investigations
      Transaminases increased                        10NOV2021       21       472       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        10NOV2021      103         6       No         No       MOD            No          3            2
    Infections and infestations
      Otitis externa                                 10NOV2021      104         8       No         No       MILD           No          3            2
    Infections and infestations
      Tularaemia                                     10NOV2021      113        35       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       10NOV2021      235         9       No         No       MILD           No          3            2
    Infections and infestations
      Urinary tract infection                        10NOV2021      251        22       No         No       MILD           No          3            2
    Investigations
      Blood creatine phosphokinase increased         10NOV2021      335       168       No         No       SEV            Yes         3            4
    Infections and infestations
      Urinary tract infection                        10NOV2021      395        23**     No         No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         10NOV2021      510        77       No         No       MOD            Yes         3            4
    Infections and infestations
      Cystitis                                       10NOV2021      519         5       No         No       MILD           No          3            2
    Investigations
      Blood cholesterol increased                    10NOV2021      567        20       No         No       LT             No          3            2
    Infections and infestations
      Pneumonia                                      10NOV2021      568        13       No         Yes      SEV            No          3            2
    Infections and infestations
      Candida infection                              10NOV2021      585         6       No         No       MILD           No          3            2
    Infections and infestations
      Parainfluenzae virus infection                 10NOV2021      588        66       No         No       MOD            No          3            4
    Investigations
      Blood creatine phosphokinase increased         10NOV2021      596        36       No         No       SEV            Yes         3            3
    Investigations
      Blood creatine phosphokinase increased         10NOV2021      653                 No         No       MILD           Yes         2            2
    Investigations
      Alanine aminotransferase increased             10NOV2021      674                 No         No       MOD            Yes         2            2
      Aspartate aminotransferase increased           10NOV2021      674                 No         No       MOD            Yes         2            2
    Infections and infestations
      Upper respiratory tract infection              10NOV2021      774        14       No         No       MILD           No          3            2
    Infections and infestations
      Influenza                                      10NOV2021      882         9       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 21 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4601/002 - 58/F/White
    Infections and infestations
      Upper respiratory tract infection              22NOV2021       32         4       No         No       MOD            No          3            2
    Infections and infestations
      Upper respiratory tract infection              22NOV2021      109        11       No         No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         22NOV2021      124        96       No         No       SEV            Yes         3            3
    Infections and infestations
      Lower respiratory tract infection              22NOV2021      219        10       No         No       MOD            Yes         3            2
    Investigations
      Blood creatine phosphokinase increased         22NOV2021      242       110       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        22NOV2021      269         8       No         No       MOD            Yes         3            2
    Infections and infestations
      COVID-19                                       22NOV2021      276        16       No         No       MILD           No          3            2
    Infections and infestations
      Diverticulitis                                 22NOV2021      345        11       No         No       MOD            Yes         3            4
    Infections and infestations
      Upper respiratory tract infection              22NOV2021      373        10       No         No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         22NOV2021      379       185       No         No       MOD            Yes         3            2
      Blood creatinine increased                     22NOV2021      379        19       No         No       MILD           No          3            2
    Infections and infestations
      Upper respiratory tract infection              22NOV2021      418        21       No         No       MOD            Yes         3            2
    Investigations
      Blood creatinine increased                     22NOV2021      442        42       No         No       MILD           No          3            2
    Infections and infestations
      Rhinitis                                       22NOV2021      470        32       No         No       MOD            No          3            2

  4601/003 - 68/F/White
    Infections and infestations
      Gastroenteritis                                14JUN2022       10         9       No         No       MOD            Yes         3            2
    Infections and infestations
      Herpes zoster                                  14JUN2022       32        49       No         Yes      SEV            No          3            2

  4701/001 - 33/F/White
    Infections and infestations
      Lower respiratory tract infection              21MAR2023       51        10       No         Yes      DEATH          Yes         1            5
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 22 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4701/001 - 33/F/White
    Infections and infestations
      Oral candidiasis                               21MAR2023       57                 No         No       MOD            Yes         2            2

  4702/002 - 69/M/Black or African American
    Investigations
      Blood creatinine increased                     14JUN2023        6        35       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             14JUN2023       22         8       No         No       LT             No          3            2
    Investigations
      Alanine aminotransferase increased             14JUN2023       30         5       No         No       SEV            No          3            2
    Investigations
      Alanine aminotransferase increased             14JUN2023       35         2       No         No       MOD            No          3            2
    Investigations
      Alanine aminotransferase increased             14JUN2023       37         5       No         No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           14JUN2023       77                 No         No       MILD           No          2            2
      Blood creatinine increased                     14JUN2023       77                 No         No       MILD           No          2            2

  4703/002 - 51/F/Unknown
    Infections and infestations
      Cellulitis                                     24MAY2023       17                 No         No       MOD            Yes         2            2
      Paronychia                                     24MAY2023       17                 No         No       MILD           Yes         2            2
    Investigations
      Alanine aminotransferase increased             24MAY2023       22        37       No         No       MOD            Yes         3            2
    Investigations
      Aspartate aminotransferase increased           24MAY2023       34        25       No         No       MOD            Yes         3            2
    Infections and infestations
      Sepsis                                         24MAY2023       41                 No         Yes      LT             No          2            2
    Investigations
      Alanine aminotransferase increased             24MAY2023       58                 No         No       MILD           Yes         2            2

  4705/001 - 63/M/White
    Infections and infestations
      Lower respiratory tract infection              23FEB2022       50         5       No         No       MILD           No          3            2
    Infections and infestations
      Lower respiratory tract infection              23FEB2022       93         8       No         No       MILD           No          3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 23 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4705/003 - 76/F/White
    Investigations
      Platelet count decreased                       27JUL2023       27                 No         No       MILD           No          5            2

  4801/001 - 54/M/Black or African American
    Infections and infestations
      COVID-19                                       22JUL2021      236         8       No         No       MOD            No          3            4
    Investigations
      Neutrophil count decreased                     22JUL2021      614        16       No         No       SEV            Yes         3            4
    Infections and infestations
      Rash pustular                                  22JUL2021      625                 No         No       MILD           No          2            2
    Infections and infestations
      Nasopharyngitis                                22JUL2021      925         5       No         No       MILD           No          3            2

  4801/002 - 54/F/White
    Infections and infestations
      Oral candidiasis                               07FEB2022       15        70       No         No       MOD            No          3            2
    Infections and infestations
      Urinary tract infection                        07FEB2022       43        16       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     07FEB2022       43        15       No         No       MILD           No          3            2
      Transaminases increased                        07FEB2022       43                 No         No       MOD            Yes         2            2
    Infections and infestations
      Pneumocystis jirovecii pneumonia               07FEB2022       55        21       No         Yes      SEV            Yes         3            3
    Investigations
      Neutrophil count decreased                     07FEB2022      218        22       No         No       MOD            No          3            2
    Investigations
      Neutrophil count decreased                     07FEB2022      242        14       No         No       SEV            No          3            2
    Investigations
      Neutrophil count decreased                     07FEB2022      247         9       No         No       SEV            No          3            2
    Investigations
      Blood phosphorus decreased                     07FEB2022      372        22       No         No       MOD            No          3            2
      Neutrophil count decreased                     07FEB2022      372        22       No         No       MOD            No          3            2

  5203/001 - 65/M/White
    Investigations
      Alanine aminotransferase increased             02DEC2021       21        63       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           02DEC2021       21                 No         No       MILD           Yes         2            2
      Blood alkaline phosphatase increased           02DEC2021       21                 No         No       MILD           No          2            2
      Blood lactate dehydrogenase increased          02DEC2021       21                 No         No       MILD           No          2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 24 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  5203/001 - 65/M/White
    Investigations
      Blood phosphorus decreased                     02DEC2021       63        64       No         No       MILD           No          3            2
    Infections and infestations
      Genital herpes simplex                         02DEC2021       98        34       No         No       MOD            No          3            2
    Investigations
      Blood thyroid stimulating hormone decreased    02DEC2021      105                 No         No       MILD           Yes         2            2
    Infections and infestations
      COVID-19                                       02DEC2021      110         6       No         No       MILD           No          3            2
    Investigations
      Blood albumin increased                        02DEC2021      126                 No         No       MILD           Yes         2            2
    Infections and infestations
      Genital herpes simplex                         02DEC2021      177        15       No         No       MILD           No          3            2
    Infections and infestations
      Genital herpes simplex                         02DEC2021      293        21       No         No       MILD           No          3            2
    Infections and infestations
      Gastrointestinal infection                     02DEC2021      362        15       No         No       MOD            No          3            2

  5203/002 - 79/M/White
    Infections and infestations
      Candida infection                              02JUN2022       21        10       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             02JUN2022       21                 No         No       MILD           Yes         2            2
      Aspartate aminotransferase increased           02JUN2022       21                 No         No       MILD           Yes         2            2
      Blood lactate dehydrogenase increased          02JUN2022       21                 No         No       MILD           Yes         2            2
    Investigations
      Blood phosphorus decreased                     02JUN2022       26        37       No         No       MILD           Yes         3            2
    Infections and infestations
      Candida infection                              02JUN2022       63                 No         No       MILD           Yes         2            2
    Investigations
      Blood creatinine increased                     02JUN2022       63                 No         No       MILD           Yes         2            2
      Blood phosphorus increased                     02JUN2022       63        10       No         No       MILD           Yes         3            2
      Glomerular filtration rate decreased           02JUN2022       63                 No         No       MOD            Yes         2            2
    Infections and infestations
      Pneumonia                                      02JUN2022       67        18       No         Yes      MOD            Yes         4            2
    Investigations
      Blood phosphorus decreased                     02JUN2022       76                 No         No       MILD           Yes         2            2

  5401/001 - 69/F/White
    Infections and infestations
      Paronychia                                     10DEC2021       84        23       No         No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 25 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  5401/001 - 69/F/White
    Investigations
      Alanine aminotransferase increased             10DEC2021       84        43       No         No       MOD            Yes         3            2
      Aspartate aminotransferase increased           10DEC2021       84        23       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       10DEC2021      100         7       No         No       MILD           No          3            2
    Infections and infestations
      Gastroenteritis                                10DEC2021      204         4       No         No       MILD           No          3            2
    Investigations
      Blood alkaline phosphatase increased           10DEC2021      232                 No         No       SEV            No          2            2
    Investigations
      Electrocardiogram QT prolonged                 10DEC2021      321       129       No         No       SEV            No          3            2

  6602/060 - 58/F/White
    Investigations
      Electrocardiogram QT prolonged                 23JAN2024       15                 No         No       SEV            Yes         5            4
    Investigations
      Alanine aminotransferase increased             23JAN2024       86        10       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           23JAN2024       86                 No         No       MILD           Yes         5            2

  7201/001 - 70/F/American Indian or Alaska Native
    Infections and infestations
      Urinary tract infection                        11JUL2022       19                 No         No       MOD            No          5            2
    Infections and infestations
      Pneumonia                                      11JUL2022       25         2       No         Yes      DEATH          No          1            2

  7201/008 - 52/M/American Indian or Alaska Native
    Infections and infestations
      Urosepsis                                      07SEP2023      111                 No         No       MOD            Yes         5            2
    Infections and infestations
      Sinusitis                                      07SEP2023      211                 No         No       MILD           Yes         5            2

  7301/001 - 63/M/White
    Infections and infestations
      Gastroenteritis                                12MAY2022       65         8       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       12MAY2022       95         6       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 26 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  7301/003 - 67/M/American Indian or Alaska Native
    Investigations
      Blood creatinine increased                     25MAY2022      147        56       No         No       MILD           Yes         3            2

  7301/005 - 63/M/American Indian or Alaska Native
    Investigations
      Aspartate aminotransferase increased           31AUG2022       43       126       No         No       MILD           Yes         3            2
    Investigations
      Blood creatinine increased                     31AUG2022      147                 No         No       MILD           Yes         5            2
    Infections and infestations
      Lower respiratory tract infection              31AUG2022      159                 No         No       MOD            No          5            4
    Investigations
      Alanine aminotransferase increased             31AUG2022      190                 No         No       MOD            Yes         5            2
      Aspartate aminotransferase increased           31AUG2022      190                 No         No       MOD            Yes         5            2

  7301/006 - 64/M/American Indian or Alaska Native
    Infections and infestations
      COVID-19                                       07DEC2022      150        13       No         No       MOD            No          3            2
    Investigations
      Alanine aminotransferase increased             07DEC2022      231        43       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           07DEC2022      231        43       No         No       MILD           Yes         3            2
    Infections and infestations
      Oesophageal candidiasis                        07DEC2022      280        22       No         No       SEV            No          3            2
    Infections and infestations
      Helicobacter infection                         07DEC2022      303        16       No         No       MOD            No          3            2
    Infections and infestations
      Pneumonia                                      07DEC2022      368        10       No         Yes      SEV            Yes         3            2
    Infections and infestations
      Upper respiratory tract infection              07DEC2022      414         7       No         No       MILD           No          3            2

  7301/009 - 25/F/American Indian or Alaska Native
    Infections and infestations
      Gastroenteritis                                23FEB2023      377         4       No         No       MILD           No          3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 27 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  7301/012 - 65/F/American Indian or Alaska Native
    Investigations
      Alanine aminotransferase increased             25OCT2023       19                 No         No       MOD            Yes         2            2
      Aspartate aminotransferase increased           25OCT2023       19                 No         No       MOD            Yes         2            2
      Blood alkaline phosphatase increased           25OCT2023       19                 No         No       MOD            Yes         2            2
    Infections and infestations
      Urosepsis                                      25OCT2023       35                 No         Yes      LT             Yes         2            4

  7501/009 - 46/F/White
    Investigations
      Aspartate aminotransferase increased           19OCT2023       40        25       No         No       MILD           No          3            2
    Investigations
      Platelet count decreased                       19OCT2023      110        21       No         No       MILD           Yes         3            2

  8402/001 - 81/F/Asian
    Infections and infestations
      Pneumonia                                      01FEB2024       12        10       No         Yes      MOD            Yes         3            4
    Investigations
      Alanine aminotransferase increased             01FEB2024       28                 No         No       SEV            Yes         5            4
      Aspartate aminotransferase increased           01FEB2024       28                 No         No       MOD            Yes         5            2

  8407/001 - 64/F/Asian
    Investigations
      Neutrophil count decreased                     07JUL2022       23        39       No         No       SEV            No          3            2
      White blood cell count decreased               07JUL2022       23        39       No         No       MOD            No          3            2
    Investigations
      Electrocardiogram QT prolonged                 07JUL2022       82         8       No         No       SEV            Yes         3            3
      White blood cell count decreased               07JUL2022       82        22       No         No       MOD            No          3            2
    Investigations
      Neutrophil count decreased                     07JUL2022      124        84       No         No       SEV            Yes         3            3
      White blood cell count decreased               07JUL2022      124        84       No         No       SEV            Yes         3            3
    Investigations
      Lymphocyte count decreased                     07JUL2022      166        43       No         No       SEV            Yes         3            2
    Investigations
      Lymphocyte count decreased                     07JUL2022      229       145       No         No       SEV            Yes         3            2
    Investigations
      Neutrophil count decreased                     07JUL2022      271        43       No         No       MOD            Yes         3            2
      White blood cell count decreased               07JUL2022      271        43       No         No       MOD            Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 28 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  8408/001 - 45/M/Asian
    Investigations
      Alanine aminotransferase increased             19APR2023        6         4       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           19APR2023        6         4       No         No       MILD           Yes         3            2
      Blood creatinine increased                     19APR2023        6         4       No         No       MILD           Yes         3            2
      Neutrophil count decreased                     19APR2023        6         4       No         No       SEV            Yes         3            3
    Investigations
      Alanine aminotransferase increased             19APR2023       14         7       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           19APR2023       14         7       No         No       MILD           Yes         3            2
      Blood creatine phosphokinase increased         19APR2023       14         7       No         No       MOD            No          3            2
      Neutrophil count decreased                     19APR2023       14         7       No         No       MOD            Yes         3            4
    Investigations
      Blood creatine phosphokinase increased         19APR2023       23        12       No         No       MILD           Yes         3            2
      Neutrophil count decreased                     19APR2023       23        20       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             19APR2023       27       145       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           19APR2023       27         8       No         No       MILD           Yes         3            2
    Investigations
      Blood creatine phosphokinase increased         19APR2023       42        88       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           19APR2023      129        43       No         No       MILD           Yes         3            2
      Neutrophil count decreased                     19APR2023      129        85       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             19APR2023      234                 No         No       MILD           Yes         2            2
      Aspartate aminotransferase increased           19APR2023      234                 No         No       MILD           Yes         2            2
    Investigations
      Blood creatine phosphokinase increased         19APR2023      301                 No         No       MOD            Yes         2            2

  8411/001 - 75/M/Asian
    Investigations
      Alanine aminotransferase increased             19AUG2022        5                 No         No       MILD           Yes         5            2
      Aspartate aminotransferase increased           19AUG2022        5       330       No         No       MILD           Yes         3            2
      Blood creatinine increased                     19AUG2022        5        69       No         No       MILD           Yes         3            2
    Investigations
      Blood creatine phosphokinase increased         19AUG2022       13        72       No         No       SEV            Yes         3            3
    Investigations
      White blood cell count decreased               19AUG2022       20        15       No         No       MILD           Yes         3            2
    Investigations
      Neutrophil count decreased                     19AUG2022       22        13       No         No       MOD            Yes         3            2
    Infections and infestations
      Pneumocystis jirovecii pneumonia               19AUG2022       66        62       No         Yes      LT             Yes         3            5
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 29 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Pralsetinib (N=108)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  8411/001 - 75/M/Asian
    Investigations
      Amylase increased                              19AUG2022       78        21       No         No       SEV            No          3            2
    Investigations
      Lipase increased                               19AUG2022       84        70       No         No       SEV            No          3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 30 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3301/001 - 59/M/Asian
    Investigations
      Alanine aminotransferase increased             21JUN2021       22       493       No         No       SEV            No          3            2
      Aspartate aminotransferase increased           21JUN2021       22       274       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       21JUN2021      241         7       No         No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           21JUN2021      323       228       Yes        No       MILD           No          3            2
    Infections and infestations
      Herpes zoster                                  21JUN2021      820                 Yes        No       MOD            No          2            4

  3301/002 - 74/F/Asian
    Infections and infestations
      COVID-19                                       12JAN2022      145         7       No         No       SEV            No          3            2
    Infections and infestations
      Vaginal infection                              12JAN2022      155                 No         No       MILD           No          2            2

  3301/003 - 54/F/Asian
    Infections and infestations
      Nasopharyngitis                                27JUL2022      127        49       No         No       MILD           No          3            2
    Infections and infestations
      Herpes zoster                                  27JUL2022      164        27       No         No       MOD            No          3            2

  3302/002 - 76/F/Asian
    Investigations
      Blood thyroid stimulating hormone decreased    26NOV2020      294        78       No         No       MILD           Yes         3            2
    Investigations
      Blood creatinine increased                     26NOV2020      371        23       Yes        No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           26NOV2020      393       222       Yes        No       MILD           Yes         3            2
      Neutrophil count decreased                     26NOV2020      393        83       Yes        No       SEV            Yes         3            3
    Investigations
      Lymphocyte count decreased                     26NOV2020      401        15       Yes        No       MOD            Yes         3            2
    Investigations
      Blood creatinine increased                     26NOV2020      436        40       Yes        No       MILD           Yes         3            2
    Investigations
      Blood creatinine increased                     26NOV2020      496        22       Yes        No       MILD           Yes         3            2
    Investigations
      Blood creatinine increased                     26NOV2020      579        22       Yes        No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 31 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3302/002 - 76/F/Asian
    Investigations
      Aspartate aminotransferase increased           26NOV2020      616         4       Yes        No       MILD           No          3            6
    Infections and infestations
      Oral candidiasis                               26NOV2020      617                 Yes        No       MOD            No          2            6
    Investigations
      Blood bicarbonate decreased                    26NOV2020      618                 Yes        No       MOD            No          2            6
    Infections and infestations
      COVID-19                                       26NOV2020      626         8       Yes        No       SEV            No          3            6
      COVID-19 pneumonia                             26NOV2020      626                 Yes        No       SEV            No          2            6

  3302/008 - 71/F/Asian
    Investigations
      Aspartate aminotransferase increased           17MAY2022       88        79       No         No       MILD           No          3            2
    Infections and infestations
      Cystitis                                       17MAY2022      112        11       Yes        No       MOD            No          3            2
    Investigations
      Platelet count decreased                       17MAY2022      121                 Yes        No       SEV            Yes         2            2
    Infections and infestations
      Pneumonia                                      17MAY2022      162                 Yes        Yes      LT             No          2            5
    Investigations
      Aspartate aminotransferase increased           17MAY2022      167         7       Yes        No       MOD            No          3            6
    Investigations
      Alanine aminotransferase increased             17MAY2022      171         2       Yes        No       MILD           No          3            6
      Blood bicarbonate decreased                    17MAY2022      171         3       Yes        No       MOD            No          3            6
    Investigations
      Aspartate aminotransferase increased           17MAY2022      174                 Yes        No       MOD            No          2            6
    Investigations
      Alanine aminotransferase increased             17MAY2022      177                 Yes        No       MILD           No          2            6

  3302/009 - 58/M/Asian
    Investigations
      Blood bicarbonate decreased                    06JAN2023        2         3       No         No       MOD            No          3            2
    Investigations
      Neutrophil count decreased                     06JAN2023       11         2       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19 pneumonia                             06JAN2023       20         9       No         Yes      SEV            No          3            4

  3302/010 - 79/F/Asian
    Infections and infestations
      Pneumonia                                      23MAR2023      291        45       No         No       MOD            No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 32 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  3303/003 - 74/M/Asian
    Investigations
      Aspartate aminotransferase increased           26DEC2022       64        21       No         No       MOD            Yes         3            2
    Investigations
      Alanine aminotransferase increased             26DEC2022      311                 Yes        No       MILD           Yes         2            2
      Aspartate aminotransferase increased           26DEC2022      311                 Yes        No       SEV            Yes         2            3
    Investigations
      Aspartate aminotransferase increased           26DEC2022      318        21       Yes        No       MILD           Yes         3            2

  3303/004 - 65/M/Asian
    Investigations
      Neutrophil count decreased                     04APR2023      288        42       Yes        No       MOD            Yes         3            2
    Investigations
      Neutrophil count decreased                     04APR2023      351                 Yes        No       SEV            Yes         5            4

  3304/001 - 67/M/Asian
    Investigations
      Neutrophil count decreased                     15JAN2024       85         8       No         No       MOD            Yes         3            2
      White blood cell count decreased               15JAN2024       85         8       No         No       MOD            Yes         3            2

  4203/001 - 60/M/NOT REPORTED
    Investigations
      Weight decreased                               03JAN2022       39                 No         No       MOD            Yes         2            2
    Investigations
      SARS-CoV-2 test positive                       03JAN2022       85         8       No         No       MOD            No          3            2

  4204/001 - 63/F/NOT REPORTED
    Investigations
      Alanine aminotransferase increased             20MAY2021       21                 No         No       MOD            Yes         2            2
      Transaminases increased                        20MAY2021       21       384       No         No       MOD            Yes         3            2
    Investigations
      Aspartate aminotransferase increased           20MAY2021       85        84       No         No       MILD           Yes         3            2
    Investigations
      Blood lactate dehydrogenase increased          20MAY2021      106       194       No         No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 33 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4204/001 - 63/F/NOT REPORTED
    Infections and infestations
      COVID-19                                       20MAY2021      317         7       No         No       MILD           Yes         3            2
    Infections and infestations
      Tongue fungal infection                        20MAY2021      968                 Yes        No       MOD            Yes         2            2
    Investigations
      Alanine aminotransferase increased             20MAY2021      988                 Yes        No       MILD           Yes         2            2
      Aspartate aminotransferase increased           20MAY2021      988                 Yes        No       MILD           Yes         2            2
      Blood lactate dehydrogenase increased          20MAY2021      988                 Yes        No       MILD           Yes         2            2
      Gamma-glutamyltransferase increased            20MAY2021      988                 Yes        No       MILD           Yes         2            2

  4205/003 - 73/F/NOT REPORTED
    Infections and infestations
      Sinusitis                                      25NOV2022      107        35       No         No       MOD            No          3            2
    Infections and infestations
      Bronchitis                                     25NOV2022      115        27       No         No       MOD            No          3            2
    Infections and infestations
      Kidney infection                               25NOV2022      206                 Yes        Yes      SEV            No          2            4
    Infections and infestations
      Paronychia                                     25NOV2022      249                 Yes        No       MILD           Yes         2            2

  4206/003 - 70/F/NOT REPORTED
    Infections and infestations
      Rhinitis                                       14DEC2022       15        57       No         No       MILD           No          3            2
    Investigations
      Gamma-glutamyltransferase increased            14DEC2022       21       100       No         No       MILD           No          3            2
      Lymphocyte count decreased                     14DEC2022       21        22       No         No       MILD           No          3            2
    Infections and infestations
      Conjunctivitis                                 14DEC2022       44        29       No         No       MILD           Yes         3            2
    Infections and infestations
      Fungal infection                               14DEC2022       51        22       No         No       MILD           Yes         3            2
    Investigations
      Blood alkaline phosphatase increased           14DEC2022       69        45       No         No       MILD           Yes         3            2
      Lymphocyte count decreased                     14DEC2022       69        22       No         No       MILD           Yes         3            2
    Investigations
      Neutrophil count decreased                     14DEC2022       90         2       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             14DEC2022      147       191       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           14DEC2022      147       191       No         No       MILD           Yes         3            2
      Blood alkaline phosphatase increased           14DEC2022      147       213       No         No       MILD           Yes         3            2
      Gamma-glutamyltransferase increased            14DEC2022      147       213       No         No       MILD           Yes         3            2
    Infections and infestations
      Rhinitis                                       14DEC2022      151         4       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 34 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4206/003 - 70/F/NOT REPORTED
    Infections and infestations
      Conjunctivitis                                 14DEC2022      170       232       No         No       MOD            Yes         3            2
    Infections and infestations
      Viral infection                                14DEC2022      216         5       No         No       MILD           No          3            2
    Infections and infestations
      Fungal infection                               14DEC2022      221        34       No         No       MILD           No          3            2
    Infections and infestations
      Viral infection                                14DEC2022      387        10       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             14DEC2022      400        22       No         No       MILD           Yes         3            2
      Gamma-glutamyltransferase increased            14DEC2022      400        22       No         No       MILD           Yes         3            2

  4208/001 - 36/M/NOT REPORTED
    Investigations
      Weight increased                               31MAR2021        1                 No         No       MOD            No          2            2
    Infections and infestations
      COVID-19                                       31MAR2021      283         2       No         No       MILD           No          3            2

  4208/003 - 70/F/NOT REPORTED
    Infections and infestations
      Urinary tract infection                        29SEP2022       16         4       No         No       MILD           No          3            2
    Infections and infestations
      Escherichia infection                          29SEP2022       54         3       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             29SEP2022       86        21       No         No       MILD           No          3            2
      Gamma-glutamyltransferase increased            29SEP2022       86                 No         No       MOD            No          2            2
    Infections and infestations
      Conjunctivitis                                 29SEP2022      126*       59**     No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             29SEP2022      170        45**     No         No       MILD           No          3            2

  4208/005 - 60/F/Other
    Infections and infestations
      Herpes zoster                                  15MAR2023       66        43**     No         No       MOD            Yes         3            2
    Investigations
      Blood creatinine increased                     15MAR2023      394                 No         No       MILD           Yes         2            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 35 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4211/001 - 65/M/NOT REPORTED
    Investigations
      Alanine aminotransferase increased             28JUN2021       19        43       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           28JUN2021       19        22       No         No       MILD           Yes         3            2
    Investigations
      Weight decreased                               28JUN2021      144        12       No         No       MILD           No          3            2

  4213/001 - 58/F/NOT REPORTED
    Investigations
      Blood creatinine increased                     15FEB2022      309       283       No         No       MOD            No          3            2
    Investigations
      Blood creatinine increased                     15FEB2022      360       232       Yes        No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         15FEB2022      528       190       Yes        No       MOD            No          3            2

  4213/002 - 77/M/NOT REPORTED
    Investigations
      Lymphocyte count decreased                     16JAN2024       22                 No         No       MOD            Yes         2            2

  4214/005 - 55/M/NOT REPORTED
    Investigations
      Neutrophil count decreased                     24AUG2022       55         9       No         No       LT             Yes         3            2
      Platelet count decreased                       24AUG2022       55         4       No         No       MOD            Yes         3            2
    Investigations
      Blood creatinine increased                     24AUG2022      261        55       Yes        No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             24AUG2022      441         8       Yes        No       MOD            Yes         3            4

  4214/006 - 62/M/NOT REPORTED
    Investigations
      Weight decreased                               15MAY2023       43        29       No         No       MOD            No          3            2
    Investigations
      Alanine aminotransferase increased             15MAY2023      111        48       No         No       SEV            Yes         3            5

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 36 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4303/001 - 79/M/White
    Investigations
      Neutrophil count decreased                     10MAY2021       43         8       No         No       SEV            Yes         3            4
    Investigations
      Neutrophil count decreased                     10MAY2021      115        10       No         No       SEV            Yes         3            4
    Investigations
      White blood cell count decreased               10MAY2021      136        36       No         No       MOD            Yes         3            2
    Infections and infestations
      COVID-19                                       10MAY2021      276        15       No         No       MILD           No          3            4

  4307/002 - 68/F/White
    Infections and infestations
      Infection                                      12MAR2021       51         5       No         No       MOD            Yes         3            2
    Investigations
      Platelet count decreased                       12MAR2021       54         8       No         No       MOD            Yes         3            2
    Infections and infestations
      Nasopharyngitis                                12MAR2021      412         8       No         No       MILD           Yes         3            2
    Infections and infestations
      Conjunctivitis                                 12MAR2021      426         9       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       12MAR2021      519        36       No         No       MOD            No          3            2
    Infections and infestations
      Urinary tract infection                        12MAR2021      532         6       No         No       MOD            No          3            2
    Infections and infestations
      Oropharyngeal candidiasis                      12MAR2021      538        17       No         No       MOD            No          3            2

  4312/002 - 61/M/White
    Infections and infestations
      Conjunctivitis                                 26OCT2020       79       170**     No         No       MILD           Yes         3            2
    Investigations
      Blood alkaline phosphatase increased           26OCT2020      270        98       No         No       MILD           No          3            2
    Investigations
      White blood cell count decreased               26OCT2020      367        22       Yes        No       MOD            Yes         3            2

  4312/003 - 48/F/White
    Investigations
      Alanine aminotransferase increased             30DEC2020       50       155       No         No       SEV            Yes         3            2
      Aspartate aminotransferase increased           30DEC2020       50       155       No         No       MILD           Yes         3            2
    Infections and infestations
      Conjunctivitis                                 30DEC2020      141       166**     No         No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 37 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4312/003 - 48/F/White
    Infections and infestations
      COVID-19                                       30DEC2020      385        32       No         No       MILD           No          3            6

  4313/001 - 60/F/White
    Infections and infestations
      Urinary tract infection                        08JUL2021      106        22       No         No       MOD            No          3            2
    Infections and infestations
      Urinary tract infection                        08JUL2021      148        64       No         No       MOD            No          3            2
    Infections and infestations
      Oral herpes                                    08JUL2021      511         7       No         No       MILD           No          3            2

  4402/002 - 43/F/White
    Infections and infestations
      Nasopharyngitis                                17OCT2022      145                 No         No       MILD           No          2            2

  4403/001 - 62/F/White
    Investigations
      Amylase increased                              19JUL2021      190                 Yes        No       MOD            No          5            2
    Investigations
      Platelet count decreased                       19JUL2021      191        35       Yes        No       SEV            No          3            2
    Infections and infestations
      Urinary tract infection                        19JUL2021      194                 Yes        No       MOD            No          5            2
    Infections and infestations
      Cytomegalovirus infection                      19JUL2021      208        18       Yes        No       MOD            No          3            2
      Epstein-Barr virus infection                   19JUL2021      208        18       Yes        No       MOD            No          3            2

  4404/002 - 61/F/White
    Infections and infestations
      Conjunctivitis                                 06NOV2020       28                 No         No       MILD           No          2            2
    Investigations
      Alanine aminotransferase increased             06NOV2020       42        42       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           06NOV2020       42        42       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       06NOV2020      757                 No         No       MILD           No          5            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 38 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4404/006 - 59/F/White
    Investigations
      Platelet count decreased                       06MAY2021       64         6       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       06MAY2021      343                 No         No       MILD           No          5            4
    Infections and infestations
      Conjunctivitis                                 06MAY2021      356                 No         No       MILD           No          5            2
    Investigations
      Transaminases increased                        06MAY2021      492                 No         No       MILD           Yes         5            2
    Infections and infestations
      Influenza                                      06MAY2021      761                 Yes        No       MILD           No          5            4

  4404/007 - 48/M/White
    Investigations
      Alanine aminotransferase increased             05OCT2021        1                 No         No       MILD           No          5            2
      Aspartate aminotransferase increased           05OCT2021        1                 No         No       MILD           No          5            2
    Infections and infestations
      Gastrointestinal infection                     05OCT2021      179         3       No         No       MILD           No          3            2
    Infections and infestations
      Pneumonia                                      05OCT2021      209         2       No         Yes      SEV            No          3            4
    Infections and infestations
      Pneumonia                                      05OCT2021      211                 No         No       SEV            No          5            2
    Investigations
      Weight decreased                               05OCT2021      239                 No         No       MILD           No          5            5

  4404/008 - 73/F/White
    Investigations
      Platelet count decreased                       21OCT2021       85        22       No         No       MILD           Yes         3            3

  4404/010 - 48/F/White
    Investigations
      Platelet count decreased                       15MAR2022      190                 Yes        No       MILD           Yes         5            2

  4406/004 - 49/M/White
    Infections and infestations
      Conjunctivitis                                 07MAR2023      126        24       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       07MAR2023      215                 No         No       MILD           No          2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 39 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4406/004 - 49/M/White
    Investigations
      Blood creatinine increased                     07MAR2023      267                 No         No       MOD            Yes         2            4

  4407/007 - 43/F/White
    Investigations
      Alanine aminotransferase increased             03MAY2023       19        10       No         No       MILD           No          3            3
      Aspartate aminotransferase increased           03MAY2023       19        10       No         No       MILD           No          3            3

  4407/008 - 59/F/White
    Investigations
      Alanine aminotransferase increased             07SEP2023       13                 No         No       MOD            Yes         2            3
      Aspartate aminotransferase increased           07SEP2023       13        10       No         No       MILD           Yes         3            3
      Gamma-glutamyltransferase increased            07SEP2023       13                 No         No       SEV            Yes         2            3
    Infections and infestations
      Herpes zoster                                  07SEP2023      230                 No         No       MOD            No          2            4

  4410/002 - 59/F/White
    Investigations
      Haemoglobin decreased                          22MAR2021       54       141       No         No       MOD            Yes         3            2

  4410/009 - 55/F/White
    Infections and infestations
      Conjunctivitis                                 28DEC2023      112                 No         No       MILD           Yes         2            2

  4412/001 - 65/F/White
    Investigations
      Blood creatinine increased                     29APR2021      369                 No         No       MILD           No          2            2
    Infections and infestations
      Conjunctivitis                                 29APR2021      503                 No         No       MILD           Yes         2            2

  4412/002 - 57/M/White
    Infections and infestations
      Dermo-hypodermitis                             05AUG2021      209                 No         No       MOD            No          2            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 40 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4412/002 - 57/M/White
    Investigations
      Blood creatinine increased                     05AUG2021      524                 No         No       MOD            Yes         2            2
    Investigations
      Blood magnesium decreased                      05AUG2021      859        26       Yes        No       MILD           No          3            2
    Investigations
      Aspartate aminotransferase increased           05AUG2021      884                 Yes        No       MILD           No          2            2

  4412/007 - 53/M/White
    Investigations
      Haemoglobin decreased                          28JUN2023      205        27       No         No       MILD           Yes         3            2

  4415/002 - 59/M/White
    Infections and infestations
      COVID-19                                       15JUN2023       93         6       No         No       MOD            No          3            4

  4503/001 - 63/F/White
    Investigations
      Alanine aminotransferase increased             09MAR2023       64       105       No         No       MILD           Yes         3            2
    Infections and infestations
      Diverticulitis                                 09MAR2023      179         9       No         Yes      SEV            No          3            2
    Infections and infestations
      Diverticulitis                                 09MAR2023      188        17       No         No       SEV            No          3            4
    Infections and infestations
      Respiratory tract infection                    09MAR2023      261         9       No         No       MOD            No          3            4

  4505/002 - 83/F/White
    Investigations
      Neutrophil count decreased                     09JUN2022       22         8       No         No       MILD           Yes         3            4
    Investigations
      Neutrophil count decreased                     09JUN2022       50         7       No         No       SEV            Yes         3            4
    Investigations
      Neutrophil count decreased                     09JUN2022       78        15       No         No       MOD            Yes         3            3
    Investigations
      Neutrophil count decreased                     09JUN2022      134        29       No         No       MOD            Yes         3            4
    Infections and infestations
      Oral herpes                                    09JUN2022      286        45       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       09JUN2022      474         3       No         Yes      MOD            No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 41 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4505/002 - 83/F/White
    Infections and infestations
      Pneumonia                                      09JUN2022      528        10       No         Yes      SEV            No          3            5

  4506/002 - 74/M/White
    Investigations
      Alanine aminotransferase increased             07AUG2023        8        77       No         No       SEV            Yes         3            3
      Aspartate aminotransferase increased           07AUG2023        8        14       No         No       MOD            Yes         3            3
    Investigations
      Aspartate aminotransferase increased           07AUG2023       85        23       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             07AUG2023      108       105       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       07AUG2023      191        22       No         No       MILD           No          3            2

  4508/001 - 64/F/White
    Investigations
      Alanine aminotransferase increased             05MAR2021       62                 No         No       SEV            Yes         2            2
    Investigations
      Aspartate aminotransferase increased           05MAR2021       83        19       No         No       MOD            Yes         3            2
      Gamma-glutamyltransferase increased            05MAR2021       83                 No         No       SEV            No          2            2
    Investigations
      Blood creatinine increased                     05MAR2021       95         3       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           05MAR2021      123        14       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           05MAR2021      158        24       No         No       MILD           Yes         3            2
    Investigations
      Aspartate aminotransferase increased           05MAR2021      202                 No         No       MILD           Yes         2            2
    Infections and infestations
      Respiratory tract infection                    05MAR2021      231                 No         Yes      SEV            No          2            6

  4511/001 - 42/F/White
    Investigations
      Neutrophil count decreased                     16FEB2022      106         7       No         No       SEV            Yes         3            4
    Infections and infestations
      Onychomycosis                                  16FEB2022      197        22       No         No       MILD           Yes         3            2
    Infections and infestations
      Respiratory tract infection                    16FEB2022      392        21       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     16FEB2022      519        82       Yes        No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 42 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4511/001 - 42/F/White
    Infections and infestations
      Viral infection                                16FEB2022      528        11       Yes        No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       16FEB2022      622        22       Yes        No       MILD           No          3            2

  4512/001 - 55/F/White
    Infections and infestations
      Conjunctivitis                                 14JAN2021        9        13       No         No       MILD           Yes         3            2
    Infections and infestations
      Conjunctivitis                                 14JAN2021       36         8       No         No       MILD           Yes         3            2
    Infections and infestations
      Respiratory tract infection                    14JAN2021      719        24       Yes        No       MILD           No          3            2

  4512/002 - 70/M/White
    Infections and infestations
      Urinary tract infection                        03MAY2022       27        13       No         No       MOD            No          3            2
    Infections and infestations
      Escherichia infection                          03MAY2022       42        24       No         Yes      SEV            No          3            2
    Infections and infestations
      Respiratory tract infection                    03MAY2022      165         6       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19                                       03MAY2022      190         8       No         No       MILD           No          3            4
    Infections and infestations
      Pyuria                                         03MAY2022      217        43       No         No       MILD           No          3            2
    Infections and infestations
      Escherichia infection                          03MAY2022      239        21       No         No       MILD           No          3            2
    Infections and infestations
      Bacteraemia                                    03MAY2022      282         6       No         No       MILD           No          3            4

  4512/003 - 72/M/White
    Investigations
      Gamma-glutamyltransferase increased            30NOV2022      402        20       Yes        No       MOD            No          3            2

  4517/009 - 37/F/White
    Infections and infestations
      Urinary tract infection                        14MAR2023       15        51       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       14MAR2023       90         4       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 43 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4517/009 - 37/F/White
    Investigations
      Neutrophil count decreased                     14MAR2023      175        16       No         Yes      SEV            No          3            2

  4702/001 - 53/M/White
    Investigations
      Blood creatinine increased                     17FEB2022      104       190       No         No       MILD           Yes         3            2
    Infections and infestations
      COVID-19                                       17FEB2022      137         9       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                17FEB2022      369         5       No         No       MILD           No          3            2

  4703/001 - 47/F/Black or African American
    Infections and infestations
      Groin abscess                                  10DEC2020       23*      153**     No         No       MILD           Yes         3            2
    Investigations
      Weight decreased                               10DEC2020      126        85       No         No       MILD           No          3            2
    Infections and infestations
      Conjunctivitis                                 10DEC2020      140       302       No         No       MOD            Yes         3            4
    Infections and infestations
      Skin infection                                 10DEC2020      602                 Yes        No       MILD           Yes         2            2
    Infections and infestations
      Urinary tract infection                        10DEC2020      920         5       Yes        No       MOD            No          3            2

  4706/001 - 74/M/Other
    Infections and infestations
      Sepsis                                         07OCT2022        7         7       No         Yes      SEV            Yes         3            6

  4903/003 - 68/F/White
    Infections and infestations
      Vulvovaginal candidiasis                       27JAN2022       97         4       No         No       MOD            Yes         3            2
    Infections and infestations
      Urinary tract infection                        27JAN2022      127        33       No         No       MOD            No          3            4
    Investigations
      Aspartate aminotransferase increased           27JAN2022      204        37       Yes        No       MILD           Yes         3            2
      Blood alkaline phosphatase increased           27JAN2022      204        37       Yes        No       MOD            Yes         3            2
    Infections and infestations
      Pneumonia legionella                           27JAN2022      240        12       Yes        Yes      SEV            No          3            4
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 44 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  4903/003 - 68/F/White
    Infections and infestations
      Oropharyngeal candidiasis                      27JAN2022      241         7       Yes        No       MOD            No          3            2
    Investigations
      Blood creatinine increased                     27JAN2022      302        21       Yes        No       MILD           No          3            2
    Investigations
      Blood thyroid stimulating hormone increased    27JAN2022      323                 Yes        No       MILD           Yes         2            2
    Infections and infestations
      Urinary tract infection                        27JAN2022      393         8       Yes        No       MOD            No          3            2
    Infections and infestations
      Urinary tract infection                        27JAN2022      408         9       Yes        No       MOD            No          3            2

  4903/004 - 38/M/White
    Investigations
      Alanine aminotransferase increased             25FEB2022      182        42       No         No       MILD           Yes         3            2
    Investigations
      Blood thyroid stimulating hormone decreased    25FEB2022      350        65       No         No       MILD           Yes         3            2

  5202/001 - 57/M/Asian
    Investigations
      Neutrophil count decreased                     04MAY2021      827         9       Yes        No       MOD            Yes         3            2

  5202/003 - 48/F/White
    Investigations
      Alanine aminotransferase increased             29SEP2021       23         8       No         No       MOD            Yes         3            2
      Aspartate aminotransferase increased           29SEP2021       23         8       No         No       MOD            Yes         3            3
    Investigations
      Alanine aminotransferase increased             29SEP2021       44        21       No         No       MOD            Yes         3            4
    Investigations
      Aspartate aminotransferase increased           29SEP2021       55        10       No         No       MOD            Yes         3            4
    Infections and infestations
      COVID-19                                       29SEP2021      276*       31**     Yes        No       MILD           No          3            2

  5202/004 - 65/M/White
    Infections and infestations
      COVID-19                                       19NOV2021       80         9       No         No       MILD           No          3            2
    Infections and infestations
      Pneumonia                                      19NOV2021      720        16       Yes        No       MOD            No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 45 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  5202/005 - 66/M/Black or African American
    Infections and infestations
      COVID-19                                       13JAN2022       13         8       No         No       MILD           No          3            2
    Investigations
      Blood creatinine increased                     13JAN2022      216                 No         No       MILD           Yes         2            5
    Investigations
      Blood alkaline phosphatase increased           13JAN2022      601        39       Yes        No       MILD           Yes         3            2
    Investigations
      Neutrophil count decreased                     13JAN2022      790        28       Yes        No       MOD            Yes         3            2
    Infections and infestations
      Pneumonia                                      13JAN2022      808        11       Yes        Yes      SEV            No          3            4

  5202/009 - 58/M/White
    Infections and infestations
      COVID-19                                       03AUG2023      164         5       No         No       MILD           No          3            2

  5203/003 - 74/M/White
    Investigations
      White blood cell count decreased               14APR2023       21        28       No         No       MILD           Yes         3            2
    Infections and infestations
      Pneumonia                                      14APR2023       37         6       No         Yes      SEV            No          3            2
    Infections and infestations
      Urinary tract infection                        14APR2023       60                 No         No       MILD           No          2            2
    Infections and infestations
      Epididymitis                                   14APR2023       63        14       No         No       MILD           No          3            2
    Infections and infestations
      Epididymitis                                   14APR2023      211         7       No         No       MOD            No          3            2
    Infections and infestations
      COVID-19                                       14APR2023      230         8       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                14APR2023      238        21       No         No       MILD           No          3            2
    Infections and infestations
      Respiratory tract infection                    14APR2023      249         5       No         No       MILD           No          3            2
    Infections and infestations
      Burn infection                                 14APR2023      294         9       No         No       MOD            No          3            2
    Infections and infestations
      Epididymitis                                   14APR2023      390         4       No         No       MILD           No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 46 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  5301/001 - 67/M/White
    Investigations
      Neutrophil count decreased                     08FEB2022        8        15       No         No       SEV            Yes         3            3
    Infections and infestations
      Nasopharyngitis                                08FEB2022      249         6       No         No       MILD           No          3            2
    Infections and infestations
      Nasopharyngitis                                08FEB2022      329         5       No         No       MILD           No          3            2
    Infections and infestations
      COVID-19 pneumonia                             08FEB2022      409         6       No         No       MOD            No          3            2

  6301/001 - 73/F/White
    Investigations
      Blood pressure increased                       12APR2023       28         1       No         No       MOD            Yes         3            4
    Infections and infestations
      Conjunctivitis                                 12APR2023       72         3       No         No       MOD            Yes         3            2
    Infections and infestations
      Conjunctivitis                                 12APR2023       83         3       No         No       MOD            Yes         3            5
    Infections and infestations
      Urinary tract infection                        12APR2023      104         5       No         No       MOD            No          3            2

  6601/002 - 40/M/White
    Infections and infestations
      Pneumonia                                      02SEP2021        3        45       No         No       MOD            No          3            2
    Infections and infestations
      Tooth infection                                02SEP2021       40         8       No         No       MOD            No          3            2

  6602/039 - 25/F/White
    Investigations
      Blood lactate dehydrogenase increased          26JUN2023       37        59       No         No       MILD           No          3            2
    Investigations
      Alanine aminotransferase increased             26JUN2023      116        47       No         No       MOD            No          3            2
      Aspartate aminotransferase increased           26JUN2023      116        47       No         No       MILD           No          3            2
    Investigations
      Blood lactate dehydrogenase increased          26JUN2023      198                 No         No       MILD           No          5            2
    Infections and infestations
      COVID-19                                       26JUN2023      263        19       Yes        Yes      MOD            No          3            4
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 47 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  6602/051 - 67/F/White
    Investigations
      Gamma-glutamyltransferase increased            15NOV2023       20        24       No         No       MILD           No          3            2

  6602/053 - 62/M/White
    Investigations
      Bilirubin conjugated increased                 07DEC2023       21        13       No         No       MILD           Yes         3            4
      Blood alkaline phosphatase increased           07DEC2023       21        13       No         No       MOD            Yes         3            4
      Gamma-glutamyltransferase increased            07DEC2023       21        16       No         No       SEV            Yes         3            4
    Investigations
      Blood lactate dehydrogenase increased          07DEC2023       36        35       No         No       SEV            Yes         3            4

  6604/025 - 70/M/White
    Investigations
      Blood albumin decreased                        02MAR2023        3                 No         No       MOD            No          2            2
      Blood uric acid increased                      02MAR2023        3         2       No         No       MILD           No          3            2
      Lymphocyte count decreased                     02MAR2023        3                 No         No       LT             Yes         2            2
    Investigations
      Gamma-glutamyltransferase increased            02MAR2023        4                 No         No       MOD            Yes         2            2
    Investigations
      Platelet count decreased                       02MAR2023        6                 No         No       MOD            Yes         2            2

  7201/002 - 64/F/American Indian or Alaska Native
    Infections and infestations
      Upper respiratory tract infection              11AUG2022      156         8       No         No       MILD           No          3            2

  7201/004 - 62/M/American Indian or Alaska Native
    Investigations
      Weight decreased                               13OCT2022       22       427       No         No       MOD            Yes         3            2
    Infections and infestations
      Gastroenteritis                                13OCT2022       87        14       No         No       MOD            No          3            2
    Investigations
      Alanine aminotransferase increased             13OCT2022      489        43       Yes        No       MILD           Yes         3            2
      Aspartate aminotransferase increased           13OCT2022      489        43       Yes        No       MILD           Yes         3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 48 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  7201/004 - 62/M/American Indian or Alaska Native
    Infections and infestations
      Urinary tract infection                        13OCT2022      593         8       Yes        No       MOD            No          3            2

  7201/007 - 74/F/American Indian or Alaska Native
    Investigations
      Alanine aminotransferase increased             16AUG2023      231        22       No         No       MILD           No          3            2
      Aspartate aminotransferase increased           16AUG2023      231        22       No         No       MILD           No          3            2

  7301/011 - 71/F/American Indian or Alaska Native
    Infections and infestations
      Respiratory tract infection viral              16AUG2023      231                 No         No       MOD            No          2            2

  8001/001 - 61/F/Asian
    Investigations
      Alanine aminotransferase increased             08AUG2022       22       213       No         No       MILD           Yes         3            2
      Aspartate aminotransferase increased           08AUG2022       22       213       No         No       MILD           Yes         3            2
      Blood alkaline phosphatase increased           08AUG2022       22       155       No         No       MILD           Yes         3            2

  8001/003 - 43/M/Asian
    Infections and infestations
      Pneumonia                                      11NOV2022       11        14       No         No       SEV            No          3            2
    Investigations
      Cytomegalovirus test positive                  11NOV2022       15         8       No         No       MILD           No          3            2
    Infections and infestations
      Herpes simplex                                 11NOV2022       18         5       No         No       MOD            No          3            2
    Investigations
      Blood creatine phosphokinase increased         11NOV2022      123                 Yes        No       MILD           No          2            2
    Infections and infestations
      COVID-19                                       11NOV2022      170                 Yes        No       MILD           No          5            2
    Infections and infestations
      Oral candidiasis                               11NOV2022      537                 Yes        No       MILD           No          2            2

  8405/001 - 44/F/Asian
    Infections and infestations
      Periodontitis                                  03JUN2022       89       467       No         No       MOD            No          3            2
    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 49 of 50

Listing of Investigations and Infections and Infestations Adverse Events, Safety-Evaluable Patients
Protocol: BO42864
    Treatment: Standard of Care (N=104)

    _________________________________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race3
      Adverse Event MedDRA                         Date of First   Study       AE                           Most
      System Organ Class                             Study Drug    Day of  Duration in  Crossover           Extreme        Caused by                Action
        Preferred Term                             Administration  Onset      Days      phase      Serious  Intensity (1)  Study Drug  Outcome (2)  Taken (3)
    _________________________________________________________________________________________________________________________________________________________

  8405/001 - 44/F/Asian
    Investigations
      Alanine aminotransferase increased             03JUN2022      127       169       No         No       MOD            Yes         3            2

  8405/002 - 48/F/Asian
    Investigations
      Aspartate aminotransferase increased           18APR2023        4                 No         No       MOD            Yes         2            2
    Investigations
      Alanine aminotransferase increased             18APR2023        7        15       No         No       MILD           Yes         3            2
    Investigations
      Alanine aminotransferase increased             18APR2023       42                 No         No       MOD            Yes         2            2

  8406/001 - 67/M/Asian
    Infections and infestations
      Oral candidiasis                               05JUL2022       43       170       No         No       MILD           Yes         3            2
    Infections and infestations
      Herpes ophthalmic                              05JUL2022      155       144       No         No       MOD            Yes         3            4
      Herpes zoster                                  05JUL2022      155        15       No         No       MOD            Yes         3            4
    Infections and infestations
      Pneumonia                                      05JUL2022      451                 Yes        No       MILD           Yes         2            2

  8407/002 - 78/F/Asian
    Infections and infestations
      Influenza                                      08FEB2023      295        18       No         No       MOD            No          3            2

    _________________________________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Severity: MILD = Grade 1 - Mild, MOD = Grade 2 - Moderate, SEV = Grade 3 - Severe, LT = Grade 4 - Life Threatening, DEATH = Grade 5 - Death.
    (2) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (3) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVINF_SE.out
18JUL2024 15:06                                                                                                                                                        Page 50 of 50

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

  - Any adverse events -                                         - Any Grade -    33 (94.3%)
                                                                 Grade 1-2        11 (31.4%)
                                                                   1               3 ( 8.6%)
                                                                   2               8 (22.9%)
                                                                 Grade 3-4        19 (54.3%)
                                                                   3              14 (40.0%)
                                                                   4               5 (14.3%)
                                                                 Grade 5           3 ( 8.6%)

  Investigations
    - Overall -                                                  - Any Grade -    19 (54.3%)
                                                                 Grade 1-2        14 (40.0%)
                                                                   1               7 (20.0%)
                                                                   2               7 (20.0%)
                                                                 Grade 3-4         5 (14.3%)
                                                                   3               5 (14.3%)
    Aspartate aminotransferase increased                         - Any Grade -     8 (22.9%)
                                                                 Grade 1-2         7 (20.0%)
                                                                   1               6 (17.1%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Alanine aminotransferase increased                           - Any Grade -     5 (14.3%)
                                                                 Grade 1-2         5 (14.3%)
                                                                   1               4 (11.4%)
                                                                   2               1 ( 2.9%)
    Blood creatinine increased                                   - Any Grade -     5 (14.3%)
                                                                 Grade 1-2         5 (14.3%)
                                                                   1               4 (11.4%)
                                                                   2               1 ( 2.9%)
    Neutrophil count decreased                                   - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   2               2 ( 5.7%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Platelet count decreased                                     - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Blood alkaline phosphatase increased                         - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Blood bicarbonate decreased                                  - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   2               2 ( 5.7%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 1 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Blood creatine phosphokinase increased                       - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Gamma-glutamyltransferase increased                          - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Amylase increased                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Blood lactate dehydrogenase increased                        - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Blood magnesium decreased                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Blood thyroid stimulating hormone increased                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Lymphocyte count decreased                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    White blood cell count decreased                             - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Infections and infestations
    - Overall -                                                  - Any Grade -    18 (51.4%)
                                                                 Grade 1-2        13 (37.1%)
                                                                   1               6 (17.1%)
                                                                   2               7 (20.0%)
                                                                 Grade 3-4         5 (14.3%)
                                                                   3               4 (11.4%)
                                                                   4               1 ( 2.9%)
    COVID-19                                                     - Any Grade -     5 (14.3%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               3 ( 8.6%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Pneumonia                                                    - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               1 ( 2.9%)
                                                                   4               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 2 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Urinary tract infection                                      - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   2               4 (11.4%)
    Oral candidiasis                                             - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    COVID-19 pneumonia                                           - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Cystitis                                                     - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Cytomegalovirus infection                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Epstein-Barr virus infection                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Herpes zoster                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Influenza                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Kidney infection                                             - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Oropharyngeal candidiasis                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Paronychia                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Pneumonia legionella                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Respiratory tract infection                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Skin infection                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Tongue fungal infection                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 3 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Viral infection                                              - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Gastrointestinal disorders
    - Overall -                                                  - Any Grade -    16 (45.7%)
                                                                 Grade 1-2        16 (45.7%)
                                                                   1              10 (28.6%)
                                                                   2               6 (17.1%)
    Constipation                                                 - Any Grade -     9 (25.7%)
                                                                 Grade 1-2         9 (25.7%)
                                                                   1               7 (20.0%)
                                                                   2               2 ( 5.7%)
    Nausea                                                       - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               2 ( 5.7%)
                                                                   2               2 ( 5.7%)
    Abdominal pain upper                                         - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               2 ( 5.7%)
                                                                   2               1 ( 2.9%)
    Diarrhoea                                                    - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               2 ( 5.7%)
                                                                   2               1 ( 2.9%)
    Dry mouth                                                    - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               3 ( 8.6%)
    Stomatitis                                                   - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   2               3 ( 8.6%)
    Abdominal pain                                               - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Haemorrhoids                                                 - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Vomiting                                                     - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Abdominal discomfort                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 4 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Ascites                                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Eructation                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Food poisoning                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Oesophagitis                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Salivary hypersecretion                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Toothache                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Respiratory, thoracic and mediastinal disorders
    - Overall -                                                  - Any Grade -    16 (45.7%)
                                                                 Grade 1-2        10 (28.6%)
                                                                   1               5 (14.3%)
                                                                   2               5 (14.3%)
                                                                 Grade 3-4         6 (17.1%)
                                                                   3               4 (11.4%)
                                                                   4               2 ( 5.7%)
    Cough                                                        - Any Grade -     7 (20.0%)
                                                                 Grade 1-2         7 (20.0%)
                                                                   1               7 (20.0%)
    Pneumonitis                                                  - Any Grade -     5 (14.3%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   2               4 (11.4%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Dysphonia                                                    - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
    Dyspnoea                                                     - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   4               1 ( 2.9%)
    Interstitial lung disease                                    - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 5 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Pleural effusion                                             - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Pneumothorax                                                 - Any Grade -     2 ( 5.7%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               1 ( 2.9%)
                                                                   4               1 ( 2.9%)
    Pulmonary embolism                                           - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Bronchopleural fistula                                       - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Lung disorder                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Nasal congestion                                             - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Pleuritic pain                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Reflux laryngitis                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Rhinorrhoea                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  General disorders and administration site conditions
    - Overall -                                                  - Any Grade -    15 (42.9%)
                                                                 Grade 1-2        13 (37.1%)
                                                                   1               9 (25.7%)
                                                                   2               4 (11.4%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)
    Asthenia                                                     - Any Grade -     6 (17.1%)
                                                                 Grade 1-2         5 (14.3%)
                                                                   1               2 ( 5.7%)
                                                                   2               3 ( 8.6%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 6 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Face oedema                                                  - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               4 (11.4%)
    Oedema peripheral                                            - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               3 ( 8.6%)
                                                                   2               1 ( 2.9%)
    Pyrexia                                                      - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               2 ( 5.7%)
                                                                   2               1 ( 2.9%)
    Chest pain                                                   - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
    Mucosal inflammation                                         - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Death                                                        - Any Grade -     1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)
    Fatigue                                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Influenza like illness                                       - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Oedema                                                       - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Pain                                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Swelling                                                     - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Blood and lymphatic system disorders
    - Overall -                                                  - Any Grade -    14 (40.0%)
                                                                 Grade 1-2         7 (20.0%)
                                                                   1               2 ( 5.7%)
                                                                   2               5 (14.3%)
                                                                 Grade 3-4         7 (20.0%)
                                                                   3               7 (20.0%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 7 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Anaemia                                                      - Any Grade -     7 (20.0%)
                                                                 Grade 1-2         5 (14.3%)
                                                                   1               2 ( 5.7%)
                                                                   2               3 ( 8.6%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Neutropenia                                                  - Any Grade -     7 (20.0%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               1 ( 2.9%)
                                                                   2               3 ( 8.6%)
                                                                 Grade 3-4         3 ( 8.6%)
                                                                   3               3 ( 8.6%)
    Leukopenia                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Lymphopenia                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Pancytopenia                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)

  Nervous system disorders
    - Overall -                                                  - Any Grade -    13 (37.1%)
                                                                 Grade 1-2        12 (34.3%)
                                                                   1              10 (28.6%)
                                                                   2               2 ( 5.7%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Dysgeusia                                                    - Any Grade -     7 (20.0%)
                                                                 Grade 1-2         7 (20.0%)
                                                                   1               5 (14.3%)
                                                                   2               2 ( 5.7%)
    Headache                                                     - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               3 ( 8.6%)
    Paraesthesia                                                 - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
    Balance disorder                                             - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypoaesthesia                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Neuralgia                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 8 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Neuropathy peripheral                                        - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Sciatica                                                     - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Taste disorder                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Metabolism and nutrition disorders
    - Overall -                                                  - Any Grade -    12 (34.3%)
                                                                 Grade 1-2        10 (28.6%)
                                                                   1               6 (17.1%)
                                                                   2               4 (11.4%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Decreased appetite                                           - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               1 ( 2.9%)
                                                                   2               2 ( 5.7%)
    Hypophosphataemia                                            - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   2               3 ( 8.6%)
    Hypoalbuminaemia                                             - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Hyponatraemia                                                - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Cell death                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Diabetes mellitus                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Hyperglycaemia                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Hyperkalaemia                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                  Page 9 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Hyperphosphatasaemia                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Hyperuricaemia                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypocalcaemia                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypoglycaemia                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypokalaemia                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Increased appetite                                           - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Musculoskeletal and connective tissue disorders
    - Overall -                                                  - Any Grade -    12 (34.3%)
                                                                 Grade 1-2        12 (34.3%)
                                                                   1               6 (17.1%)
                                                                   2               6 (17.1%)
    Arthralgia                                                   - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               4 (11.4%)
    Back pain                                                    - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   2               2 ( 5.7%)
    Bone pain                                                    - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Myalgia                                                      - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Hypercreatinaemia                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Limb mass                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Muscular weakness                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 10 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Neck pain                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Osteoarthritis                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Pain in extremity                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Pubic pain                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Vascular disorders
    - Overall -                                                  - Any Grade -    12 (34.3%)
                                                                 Grade 1-2         9 (25.7%)
                                                                   1               4 (11.4%)
                                                                   2               5 (14.3%)
                                                                 Grade 3-4         3 ( 8.6%)
                                                                   3               3 ( 8.6%)
    Hypertension                                                 - Any Grade -    10 (28.6%)
                                                                 Grade 1-2         8 (22.9%)
                                                                   1               3 ( 8.6%)
                                                                   2               5 (14.3%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Blood pressure inadequately controlled                       - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Capillary fragility                                          - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypotension                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)

  No Coding available
    - Overall -                                                  - Any Grade -    10 (28.6%)
                                                                 Grade 1-2         6 (17.1%)
                                                                   1               3 ( 8.6%)
                                                                   2               3 ( 8.6%)
                                                                 Grade 3-4         3 ( 8.6%)
                                                                   3               2 ( 5.7%)
                                                                   4               1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 11 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    No Coding available                                          - Any Grade -    10 (28.6%)
                                                                 Grade 1-2         6 (17.1%)
                                                                   1               3 ( 8.6%)
                                                                   2               3 ( 8.6%)
                                                                 Grade 3-4         3 ( 8.6%)
                                                                   3               2 ( 5.7%)
                                                                   4               1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)

  Skin and subcutaneous tissue disorders
    - Overall -                                                  - Any Grade -     9 (25.7%)
                                                                 Grade 1-2         9 (25.7%)
                                                                   1               8 (22.9%)
                                                                   2               1 ( 2.9%)
    Rash                                                         - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               4 (11.4%)
    Alopecia                                                     - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
    Dermatitis                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Dermatitis acneiform                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Dry skin                                                     - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hair growth abnormal                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hirsutism                                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Nail dystrophy                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Nail ridging                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Palmar-plantar erythrodysaesthesia syndrome                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Pruritus                                                     - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 12 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Skin reaction                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Skin ulcer                                                   - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Reproductive system and breast disorders
    - Overall -                                                  - Any Grade -     6 (17.1%)
                                                                 Grade 1-2         6 (17.1%)
                                                                   1               2 ( 5.7%)
                                                                   2               4 (11.4%)
    Erectile dysfunction                                         - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Prostatitis                                                  - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   2               2 ( 5.7%)
    Intermenstrual bleeding                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Vulvovaginal dryness                                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Eye disorders
    - Overall -                                                  - Any Grade -     5 (14.3%)
                                                                 Grade 1-2         5 (14.3%)
                                                                   1               4 (11.4%)
                                                                   2               1 ( 2.9%)
    Eyelid oedema                                                - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         4 (11.4%)
                                                                   1               3 ( 8.6%)
                                                                   2               1 ( 2.9%)
    Dry eye                                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Injury, poisoning and procedural complications
    - Overall -                                                  - Any Grade -     4 (11.4%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 13 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Lumbar vertebral fracture                                    - Any Grade -     2 ( 5.7%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               2 ( 5.7%)
    Clavicle fracture                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Eyelid abrasion                                              - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Limb injury                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Rib fracture                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Skin abrasion                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Cardiac disorders
    - Overall -                                                  - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Cardiac failure                                              - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Extrasystoles                                                - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Palpitations                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Endocrine disorders
    - Overall -                                                  - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         3 ( 8.6%)
                                                                   1               1 ( 2.9%)
                                                                   2               2 ( 5.7%)
    Adrenal insufficiency                                        - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Hyperthyroidism                                              - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 14 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Hypothyroidism                                               - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Thyroiditis                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Hepatobiliary disorders
    - Overall -                                                  - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
                                                                 Grade 3-4         2 ( 5.7%)
                                                                   3               1 ( 2.9%)
                                                                   4               1 ( 2.9%)
    Hepatic cytolysis                                            - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
    Hepatic pain                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
    Hypertransaminasaemia                                        - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   4               1 ( 2.9%)

  Neoplasms benign, malignant and unspecified (incl cysts and
  polyps)
    - Overall -                                                  - Any Grade -     3 ( 8.6%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)
    Cancer pain                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Metastases to central nervous system                         - Any Grade -     1 ( 2.9%)
                                                                 Grade 5           1 ( 2.9%)
    Thyroid adenoma                                              - Any Grade -     1 ( 2.9%)
                                                                 Grade 3-4         1 ( 2.9%)
                                                                   3               1 ( 2.9%)

  Psychiatric disorders
    - Overall -                                                  - Any Grade -     2 ( 5.7%)
                                                                 Grade 1-2         2 ( 5.7%)
                                                                   1               2 ( 5.7%)
    Irritability                                                 - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 15 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade -
Cross Over Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                                                       Pralsetinib
    MedDRA Preferred Term                                        Grade              (N=35)
  ___________________________________________________________________________________________

    Libido decreased                                             - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   1               1 ( 2.9%)

  Ear and labyrinth disorders
    - Overall -                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Vertigo                                                      - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  Renal and urinary disorders
    - Overall -                                                  - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)
    Urinary tract obstruction                                    - Any Grade -     1 ( 2.9%)
                                                                 Grade 1-2         1 ( 2.9%)
                                                                   2               1 ( 2.9%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  Only AEs with onset during the cross-over period are displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_XOVER_SE.out
18JUL2024 16:35                                                                 Page 16 of 16

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  - Any adverse events -         - Any Grade -    108 ( 100%)    104 ( 100%)     212 ( 100%)
                                 Grade 1-2         25 (23.1%)     45 (43.3%)      70 (33.0%)
                                   1                5 ( 4.6%)      6 ( 5.8%)      11 ( 5.2%)
                                   2               20 (18.5%)     39 (37.5%)      59 (27.8%)
                                 Grade 3-4         69 (63.9%)     54 (51.9%)     123 (58.0%)
                                   3               62 (57.4%)     47 (45.2%)     109 (51.4%)
                                   4                7 ( 6.5%)      7 ( 6.7%)      14 ( 6.6%)
                                 Grade 5           14 (13.0%)      5 ( 4.8%)      19 ( 9.0%)

  Gastrointestinal disorders
    - Overall -                  - Any Grade -     84 (77.8%)     78 (75.0%)     162 (76.4%)
                                 Grade 1-2         71 (65.7%)     71 (68.3%)     142 (67.0%)
                                   1               36 (33.3%)     33 (31.7%)      69 (32.5%)
                                   2               35 (32.4%)     38 (36.5%)      73 (34.4%)
                                 Grade 3-4         13 (12.0%)      6 ( 5.8%)      19 ( 9.0%)
                                   3               13 (12.0%)      6 ( 5.8%)      19 ( 9.0%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Constipation                 - Any Grade -     46 (42.6%)     30 (28.8%)      76 (35.8%)
                                 Grade 1-2         45 (41.7%)     30 (28.8%)      75 (35.4%)
                                   1               31 (28.7%)     22 (21.2%)      53 (25.0%)
                                   2               14 (13.0%)      8 ( 7.7%)      22 (10.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Nausea                       - Any Grade -     20 (18.5%)     48 (46.2%)      68 (32.1%)
                                 Grade 1-2         19 (17.6%)     48 (46.2%)      67 (31.6%)
                                   1               13 (12.0%)     24 (23.1%)      37 (17.5%)
                                   2                6 ( 5.6%)     24 (23.1%)      30 (14.2%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Diarrhoea                    - Any Grade -     40 (37.0%)     22 (21.2%)      62 (29.2%)
                                 Grade 1-2         36 (33.3%)     19 (18.3%)      55 (25.9%)
                                   1               18 (16.7%)     12 (11.5%)      30 (14.2%)
                                   2               18 (16.7%)      7 ( 6.7%)      25 (11.8%)
                                 Grade 3-4          4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                   3                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
    Stomatitis                   - Any Grade -     15 (13.9%)      8 ( 7.7%)      23 (10.8%)
                                 Grade 1-2         14 (13.0%)      8 ( 7.7%)      22 (10.4%)
                                   1                9 ( 8.3%)      3 ( 2.9%)      12 ( 5.7%)
                                   2                5 ( 4.6%)      5 ( 4.8%)      10 ( 4.7%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Vomiting                     - Any Grade -     10 ( 9.3%)     11 (10.6%)      21 ( 9.9%)
                                 Grade 1-2         10 ( 9.3%)     11 (10.6%)      21 ( 9.9%)
                                   1                6 ( 5.6%)      6 ( 5.8%)      12 ( 5.7%)
                                   2                4 ( 3.7%)      5 ( 4.8%)       9 ( 4.2%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 1 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Abdominal pain               - Any Grade -     11 (10.2%)      8 ( 7.7%)      19 ( 9.0%)
                                 Grade 1-2          8 ( 7.4%)      8 ( 7.7%)      16 ( 7.5%)
                                   1                6 ( 5.6%)      4 ( 3.8%)      10 ( 4.7%)
                                   2                2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                 Grade 3-4          3 ( 2.8%)      0               3 ( 1.4%)
                                   3                3 ( 2.8%)      0               3 ( 1.4%)
    Abdominal pain upper         - Any Grade -     10 ( 9.3%)      9 ( 8.7%)      19 ( 9.0%)
                                 Grade 1-2         10 ( 9.3%)      9 ( 8.7%)      19 ( 9.0%)
                                   1                7 ( 6.5%)      8 ( 7.7%)      15 ( 7.1%)
                                   2                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
    Dry mouth                    - Any Grade -     14 (13.0%)      4 ( 3.8%)      18 ( 8.5%)
                                 Grade 1-2         14 (13.0%)      4 ( 3.8%)      18 ( 8.5%)
                                   1               10 ( 9.3%)      3 ( 2.9%)      13 ( 6.1%)
                                   2                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
    Dyspepsia                    - Any Grade -      8 ( 7.4%)      3 ( 2.9%)      11 ( 5.2%)
                                 Grade 1-2          8 ( 7.4%)      3 ( 2.9%)      11 ( 5.2%)
                                   1                7 ( 6.5%)      0               7 ( 3.3%)
                                   2                1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
    Dysphagia                    - Any Grade -      4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                 Grade 1-2          4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                   1                4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
    Gastrooesophageal reflux     - Any Grade -      4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
    disease
                                 Grade 1-2          4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                   1                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Aphthous ulcer               - Any Grade -      1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 1-2          1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                   1                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Ascites                      - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Odynophagia                  - Any Grade -      2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                 Grade 1-2          2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Abdominal discomfort         - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
    Abdominal distension         - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 2 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Haemorrhoids                 - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Toothache                    - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Flatulence                   - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Haematochezia                - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
    Oral pain                    - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Abdominal pain lower         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Anal haemorrhage             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Apical granuloma             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Benign pancreatic            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    hyperenzymaemia
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Dental caries                - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Enteritis                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Enterocolitis                - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Gastric hypomotility         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Gastrointestinal disorder    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 3 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Gastrointestinal             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
    haemorrhage
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Gastrointestinal mucosa      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    hyperaemia
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Gingival bleeding            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Hiatus hernia                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Intestinal obstruction       - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Intestinal perforation       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Intra-abdominal haematoma    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Lip dry                      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Lip haemorrhage              - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Oesophageal discomfort       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Oral dysaesthesia            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Pancreatic pseudocyst        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Pancreatitis acute           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Paraesthesia oral            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Peritoneal disorder          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 4 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Proctalgia                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Rectal fissure               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Rectal haemorrhage           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Salivary hypersecretion      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Upper gastrointestinal       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    haemorrhage
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  General disorders and
  administration site
  conditions
    - Overall -                  - Any Grade -     74 (68.5%)     81 (77.9%)     155 (73.1%)
                                 Grade 1-2         63 (58.3%)     72 (69.2%)     135 (63.7%)
                                   1               38 (35.2%)     37 (35.6%)      75 (35.4%)
                                   2               25 (23.1%)     35 (33.7%)      60 (28.3%)
                                 Grade 3-4          9 ( 8.3%)      9 ( 8.7%)      18 ( 8.5%)
                                   3                9 ( 8.3%)      9 ( 8.7%)      18 ( 8.5%)
                                 Grade 5            2 ( 1.9%)      0               2 ( 0.9%)
    Asthenia                     - Any Grade -     26 (24.1%)     38 (36.5%)      64 (30.2%)
                                 Grade 1-2         24 (22.2%)     34 (32.7%)      58 (27.4%)
                                   1               15 (13.9%)     16 (15.4%)      31 (14.6%)
                                   2                9 ( 8.3%)     18 (17.3%)      27 (12.7%)
                                 Grade 3-4          2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   3                2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
    Fatigue                      - Any Grade -     19 (17.6%)     23 (22.1%)      42 (19.8%)
                                 Grade 1-2         16 (14.8%)     21 (20.2%)      37 (17.5%)
                                   1                8 ( 7.4%)     12 (11.5%)      20 ( 9.4%)
                                   2                8 ( 7.4%)      9 ( 8.7%)      17 ( 8.0%)
                                 Grade 3-4          3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                   3                3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
    Pyrexia                      - Any Grade -     24 (22.2%)     11 (10.6%)      35 (16.5%)
                                 Grade 1-2         23 (21.3%)     10 ( 9.6%)      33 (15.6%)
                                   1               16 (14.8%)     10 ( 9.6%)      26 (12.3%)
                                   2                7 ( 6.5%)      0               7 ( 3.3%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 5 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Oedema peripheral            - Any Grade -     14 (13.0%)     14 (13.5%)      28 (13.2%)
                                 Grade 1-2         14 (13.0%)     14 (13.5%)      28 (13.2%)
                                   1               11 (10.2%)     10 ( 9.6%)      21 ( 9.9%)
                                   2                3 ( 2.8%)      4 ( 3.8%)       7 ( 3.3%)
    Mucosal inflammation         - Any Grade -      8 ( 7.4%)     12 (11.5%)      20 ( 9.4%)
                                 Grade 1-2          8 ( 7.4%)     12 (11.5%)      20 ( 9.4%)
                                   1                5 ( 4.6%)      9 ( 8.7%)      14 ( 6.6%)
                                   2                3 ( 2.8%)      3 ( 2.9%)       6 ( 2.8%)
    Chest pain                   - Any Grade -      7 ( 6.5%)      9 ( 8.7%)      16 ( 7.5%)
                                 Grade 1-2          7 ( 6.5%)      8 ( 7.7%)      15 ( 7.1%)
                                   1                7 ( 6.5%)      5 ( 4.8%)      12 ( 5.7%)
                                   2                0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pain                         - Any Grade -      4 ( 3.7%)      9 ( 8.7%)      13 ( 6.1%)
                                 Grade 1-2          3 ( 2.8%)      9 ( 8.7%)      12 ( 5.7%)
                                   1                3 ( 2.8%)      5 ( 4.8%)       8 ( 3.8%)
                                   2                0              4 ( 3.8%)       4 ( 1.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Oedema                       - Any Grade -      3 ( 2.8%)      5 ( 4.8%)       8 ( 3.8%)
                                 Grade 1-2          3 ( 2.8%)      5 ( 4.8%)       8 ( 3.8%)
                                   1                2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Malaise                      - Any Grade -      4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                 Grade 1-2          2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   1                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Face oedema                  - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          5 ( 4.6%)      0               5 ( 2.4%)
                                   1                5 ( 4.6%)      0               5 ( 2.4%)
    Influenza like illness       - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
    Chills                       - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    General physical health      - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    deterioration
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Illness                      - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 6 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Swelling face                - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Catheter site pain           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Chest discomfort             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Death                        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Feeling abnormal             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Gait disturbance             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Ill-defined disorder         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Non-cardiac chest pain       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Peripheral swelling          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Serositis                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Suprapubic pain              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Vaccination site swelling    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)

  Investigations
    - Overall -                  - Any Grade -     73 (67.6%)     56 (53.8%)     129 (60.8%)
                                 Grade 1-2         48 (44.4%)     42 (40.4%)      90 (42.5%)
                                   1               30 (27.8%)     23 (22.1%)      53 (25.0%)
                                   2               18 (16.7%)     19 (18.3%)      37 (17.5%)
                                 Grade 3-4         25 (23.1%)     14 (13.5%)      39 (18.4%)
                                   3               22 (20.4%)     12 (11.5%)      34 (16.0%)
                                   4                3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 7 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Aspartate aminotransferase   - Any Grade -     43 (39.8%)     18 (17.3%)      61 (28.8%)
    increased
                                 Grade 1-2         43 (39.8%)     18 (17.3%)      61 (28.8%)
                                   1               33 (30.6%)     12 (11.5%)      45 (21.2%)
                                   2               10 ( 9.3%)      6 ( 5.8%)      16 ( 7.5%)
    Alanine aminotransferase     - Any Grade -     38 (35.2%)     21 (20.2%)      59 (27.8%)
    increased
                                 Grade 1-2         34 (31.5%)     16 (15.4%)      50 (23.6%)
                                   1               27 (25.0%)     10 ( 9.6%)      37 (17.5%)
                                   2                7 ( 6.5%)      6 ( 5.8%)      13 ( 6.1%)
                                 Grade 3-4          4 ( 3.7%)      5 ( 4.8%)       9 ( 4.2%)
                                   3                3 ( 2.8%)      5 ( 4.8%)       8 ( 3.8%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Blood creatinine increased   - Any Grade -     25 (23.1%)      8 ( 7.7%)      33 (15.6%)
                                 Grade 1-2         25 (23.1%)      8 ( 7.7%)      33 (15.6%)
                                   1               21 (19.4%)      5 ( 4.8%)      26 (12.3%)
                                   2                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
    Neutrophil count decreased   - Any Grade -     15 (13.9%)      9 ( 8.7%)      24 (11.3%)
                                 Grade 1-2          5 ( 4.6%)      3 ( 2.9%)       8 ( 3.8%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                 Grade 3-4         10 ( 9.3%)      6 ( 5.8%)      16 ( 7.5%)
                                   3                9 ( 8.3%)      5 ( 4.8%)      14 ( 6.6%)
                                   4                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Platelet count decreased     - Any Grade -      8 ( 7.4%)      5 ( 4.8%)      13 ( 6.1%)
                                 Grade 1-2          6 ( 5.6%)      5 ( 4.8%)      11 ( 5.2%)
                                   1                4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                   2                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    White blood cell count       - Any Grade -      8 ( 7.4%)      3 ( 2.9%)      11 ( 5.2%)
    decreased
                                 Grade 1-2          5 ( 4.6%)      3 ( 2.9%)       8 ( 3.8%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   2                3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                 Grade 3-4          3 ( 2.8%)      0               3 ( 1.4%)
                                   3                3 ( 2.8%)      0               3 ( 1.4%)
    Blood alkaline phosphatase   - Any Grade -      6 ( 5.6%)      4 ( 3.8%)      10 ( 4.7%)
    increased
                                 Grade 1-2          5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                   1                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 8 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Blood creatine               - Any Grade -     10 ( 9.3%)      0              10 ( 4.7%)
    phosphokinase increased
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 3-4          6 ( 5.6%)      0               6 ( 2.8%)
                                   3                6 ( 5.6%)      0               6 ( 2.8%)
    Blood lactate dehydrogenase  - Any Grade -      6 ( 5.6%)      3 ( 2.9%)       9 ( 4.2%)
    increased
                                 Grade 1-2          6 ( 5.6%)      2 ( 1.9%)       8 ( 3.8%)
                                   1                6 ( 5.6%)      2 ( 1.9%)       8 ( 3.8%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Gamma-glutamyltransferase    - Any Grade -      2 ( 1.9%)      7 ( 6.7%)       9 ( 4.2%)
    increased
                                 Grade 1-2          2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   1                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          0              3 ( 2.9%)       3 ( 1.4%)
                                   3                0              3 ( 2.9%)       3 ( 1.4%)
    Weight decreased             - Any Grade -      2 ( 1.9%)      6 ( 5.8%)       8 ( 3.8%)
                                 Grade 1-2          2 ( 1.9%)      6 ( 5.8%)       8 ( 3.8%)
                                   1                1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
                                   2                1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
    Lymphocyte count decreased   - Any Grade -      4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                 Grade 1-2          3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
                                   4                0              1 ( 1.0%)       1 ( 0.5%)
    Transaminases increased      - Any Grade -      4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                 Grade 1-2          4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   2                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Amylase increased            - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Blood phosphorus decreased   - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                  Page 9 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Blood thyroid stimulating    - Any Grade -      2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
    hormone decreased
                                 Grade 1-2          2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   1                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
    Electrocardiogram QT         - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
    prolonged
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          3 ( 2.8%)      0               3 ( 1.4%)
                                   3                3 ( 2.8%)      0               3 ( 1.4%)
    Haemoglobin decreased        - Any Grade -      2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                 Grade 1-2          2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Lipase increased             - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Blood bicarbonate decreased  - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Blood cholesterol increased  - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Weight increased             - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Bilirubin conjugated         - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    increased
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Blood bilirubin increased    - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    SARS-CoV-2 test positive     - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 10 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Blood albumin decreased      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Blood albumin increased      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Blood glucose increased      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Blood phosphorus increased   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Blood pressure increased     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Blood thyroid stimulating    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    hormone increased
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Blood uric acid increased    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Cytomegalovirus test         - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
    positive
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Ejection fraction decreased  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Escherichia test positive    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Glomerular filtration rate   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    decreased
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Nitrite urine present        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Oxygen saturation decreased  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Protein total decreased      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Streptococcus test positive  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 11 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Transaminases abnormal       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  Infections and infestations
    - Overall -                  - Any Grade -     73 (67.6%)     52 (50.0%)     125 (59.0%)
                                 Grade 1-2         45 (41.7%)     42 (40.4%)      87 (41.0%)
                                   1               15 (13.9%)     21 (20.2%)      36 (17.0%)
                                   2               30 (27.8%)     21 (20.2%)      51 (24.1%)
                                 Grade 3-4         23 (21.3%)     10 ( 9.6%)      33 (15.6%)
                                   3               19 (17.6%)     10 ( 9.6%)      29 (13.7%)
                                   4                4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 5            5 ( 4.6%)      0               5 ( 2.4%)
    COVID-19                     - Any Grade -     21 (19.4%)     20 (19.2%)      41 (19.3%)
                                 Grade 1-2         21 (19.4%)     19 (18.3%)      40 (18.9%)
                                   1               17 (15.7%)     16 (15.4%)      33 (15.6%)
                                   2                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pneumonia                    - Any Grade -     19 (17.6%)      6 ( 5.8%)      25 (11.8%)
                                 Grade 1-2          9 ( 8.3%)      2 ( 1.9%)      11 ( 5.2%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                8 ( 7.4%)      2 ( 1.9%)      10 ( 4.7%)
                                 Grade 3-4          7 ( 6.5%)      4 ( 3.8%)      11 ( 5.2%)
                                   3                7 ( 6.5%)      4 ( 3.8%)      11 ( 5.2%)
                                 Grade 5            3 ( 2.8%)      0               3 ( 1.4%)
    Urinary tract infection      - Any Grade -     17 (15.7%)      8 ( 7.7%)      25 (11.8%)
                                 Grade 1-2         15 (13.9%)      8 ( 7.7%)      23 (10.8%)
                                   1                5 ( 4.6%)      2 ( 1.9%)       7 ( 3.3%)
                                   2               10 ( 9.3%)      6 ( 5.8%)      16 ( 7.5%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Nasopharyngitis              - Any Grade -      8 ( 7.4%)      6 ( 5.8%)      14 ( 6.6%)
                                 Grade 1-2          8 ( 7.4%)      6 ( 5.8%)      14 ( 6.6%)
                                   1                7 ( 6.5%)      6 ( 5.8%)      13 ( 6.1%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Conjunctivitis               - Any Grade -      0             13 (12.5%)      13 ( 6.1%)
                                 Grade 1-2          0             13 (12.5%)      13 ( 6.1%)
                                   1                0              9 ( 8.7%)       9 ( 4.2%)
                                   2                0              4 ( 3.8%)       4 ( 1.9%)
    Herpes zoster                - Any Grade -      6 ( 5.6%)      4 ( 3.8%)      10 ( 4.7%)
                                 Grade 1-2          4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                3 ( 2.8%)      4 ( 3.8%)       7 ( 3.3%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 12 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Gastroenteritis              - Any Grade -      8 ( 7.4%)      1 ( 1.0%)       9 ( 4.2%)
                                 Grade 1-2          8 ( 7.4%)      1 ( 1.0%)       9 ( 4.2%)
                                   1                4 ( 3.7%)      0               4 ( 1.9%)
                                   2                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
    Respiratory tract infection  - Any Grade -      1 ( 0.9%)      5 ( 4.8%)       6 ( 2.8%)
                                 Grade 1-2          1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                   1                0              3 ( 2.9%)       3 ( 1.4%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Upper respiratory tract      - Any Grade -      5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
    infection
                                 Grade 1-2          5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
                                   1                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Cystitis                     - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          5 ( 4.6%)      0               5 ( 2.4%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Lower respiratory tract      - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
    infection
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Paronychia                   - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          5 ( 4.6%)      0               5 ( 2.4%)
                                   1                5 ( 4.6%)      0               5 ( 2.4%)
    Fungal infection             - Any Grade -      3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                 Grade 1-2          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   1                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
    Oral candidiasis             - Any Grade -      3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                 Grade 1-2          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                3 ( 2.8%)      0               3 ( 1.4%)
    Pneumocystis jirovecii       - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
    pneumonia
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          3 ( 2.8%)      0               3 ( 1.4%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    COVID-19 pneumonia           - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 13 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Infection                    - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Influenza                    - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Pharyngitis                  - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Rhinitis                     - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Sepsis                       - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Bronchitis                   - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Candida infection            - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Device related infection     - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Diverticulitis               - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Escherichia infection        - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Gastrointestinal infection   - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 14 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Oral fungal infection        - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Oral herpes                  - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
    Oropharyngeal candidiasis    - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Pneumonia cytomegaloviral    - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Pyelonephritis               - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Sinusitis                    - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Tongue fungal infection      - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Urosepsis                    - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Viral infection              - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Atypical pneumonia           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Bacteraemia                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Bronchopulmonary             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    aspergillosis
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Burn infection               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 15 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Cellulitis                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Cytomegalovirus infection    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Dermo-hypodermitis           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Epididymitis                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Erysipelas                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Escherichia urinary tract    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    infection
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Gastroenteritis viral        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Genital herpes simplex       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Groin abscess                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Helicobacter infection       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Herpes ophthalmic            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Herpes simplex               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Localised infection          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Nail infection               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Oesophageal candidiasis      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 16 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Oesophageal infection        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Onychomycosis                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Otitis externa               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Parainfluenzae virus         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    infection
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Periodontitis                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Pleural infection            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Pneumonia legionella         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Pseudomembranous colitis     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Pustule                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Pyelonephritis acute         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Pyuria                       - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Q fever                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Rash pustular                - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Respiratory tract infection  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
    viral
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Severe acute respiratory     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    syndrome
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 17 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Spontaneous bacterial        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    peritonitis
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Staphylococcal sepsis        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Streptococcal infection      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Tooth infection              - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Tularaemia                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Vaginal infection            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Vascular device infection    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Vulvovaginal candidiasis     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)

  Blood and lymphatic system
  disorders
    - Overall -                  - Any Grade -     62 (57.4%)     54 (51.9%)     116 (54.7%)
                                 Grade 1-2         36 (33.3%)     32 (30.8%)      68 (32.1%)
                                   1                9 ( 8.3%)      7 ( 6.7%)      16 ( 7.5%)
                                   2               27 (25.0%)     25 (24.0%)      52 (24.5%)
                                 Grade 3-4         26 (24.1%)     22 (21.2%)      48 (22.6%)
                                   3               22 (20.4%)     18 (17.3%)      40 (18.9%)
                                   4                4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
    Anaemia                      - Any Grade -     49 (45.4%)     45 (43.3%)      94 (44.3%)
                                 Grade 1-2         36 (33.3%)     32 (30.8%)      68 (32.1%)
                                   1               14 (13.0%)      9 ( 8.7%)      23 (10.8%)
                                   2               22 (20.4%)     23 (22.1%)      45 (21.2%)
                                 Grade 3-4         13 (12.0%)     13 (12.5%)      26 (12.3%)
                                   3               11 (10.2%)     12 (11.5%)      23 (10.8%)
                                   4                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 18 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Neutropenia                  - Any Grade -     26 (24.1%)     19 (18.3%)      45 (21.2%)
                                 Grade 1-2         15 (13.9%)     10 ( 9.6%)      25 (11.8%)
                                   1                6 ( 5.6%)      4 ( 3.8%)      10 ( 4.7%)
                                   2                9 ( 8.3%)      6 ( 5.8%)      15 ( 7.1%)
                                 Grade 3-4         11 (10.2%)      9 ( 8.7%)      20 ( 9.4%)
                                   3               11 (10.2%)      7 ( 6.7%)      18 ( 8.5%)
                                   4                0              2 ( 1.9%)       2 ( 0.9%)
    Leukopenia                   - Any Grade -     12 (11.1%)      5 ( 4.8%)      17 ( 8.0%)
                                 Grade 1-2         10 ( 9.3%)      3 ( 2.9%)      13 ( 6.1%)
                                   1                7 ( 6.5%)      2 ( 1.9%)       9 ( 4.2%)
                                   2                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                 Grade 3-4          2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   3                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
    Thrombocytopenia             - Any Grade -      4 ( 3.7%)     11 (10.6%)      15 ( 7.1%)
                                 Grade 1-2          2 ( 1.9%)      7 ( 6.7%)       9 ( 4.2%)
                                   1                2 ( 1.9%)      5 ( 4.8%)       7 ( 3.3%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   3                0              3 ( 2.9%)       3 ( 1.4%)
                                   4                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Lymphopenia                  - Any Grade -      5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
                                 Grade 1-2          4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Febrile neutropenia          - Any Grade -      1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 3-4          1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                   3                0              3 ( 2.9%)       3 ( 1.4%)
                                   4                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Leukocytosis                 - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Febrile bone marrow aplasia  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Thrombocytosis               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 19 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  Respiratory, thoracic and
  mediastinal disorders
    - Overall -                  - Any Grade -     58 (53.7%)     48 (46.2%)     106 (50.0%)
                                 Grade 1-2         43 (39.8%)     41 (39.4%)      84 (39.6%)
                                   1               27 (25.0%)     24 (23.1%)      51 (24.1%)
                                   2               16 (14.8%)     17 (16.3%)      33 (15.6%)
                                 Grade 3-4         10 ( 9.3%)      5 ( 4.8%)      15 ( 7.1%)
                                   3                8 ( 7.4%)      5 ( 4.8%)      13 ( 6.1%)
                                   4                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 5            5 ( 4.6%)      2 ( 1.9%)       7 ( 3.3%)
    Cough                        - Any Grade -     28 (25.9%)     10 ( 9.6%)      38 (17.9%)
                                 Grade 1-2         26 (24.1%)     10 ( 9.6%)      36 (17.0%)
                                   1               22 (20.4%)      7 ( 6.7%)      29 (13.7%)
                                   2                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Dyspnoea                     - Any Grade -     16 (14.8%)     19 (18.3%)      35 (16.5%)
                                 Grade 1-2         15 (13.9%)     15 (14.4%)      30 (14.2%)
                                   1                7 ( 6.5%)     11 (10.6%)      18 ( 8.5%)
                                   2                8 ( 7.4%)      4 ( 3.8%)      12 ( 5.7%)
                                 Grade 3-4          1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
                                   3                1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Epistaxis                    - Any Grade -     11 (10.2%)      3 ( 2.9%)      14 ( 6.6%)
                                 Grade 1-2         11 (10.2%)      2 ( 1.9%)      13 ( 6.1%)
                                   1                8 ( 7.4%)      2 ( 1.9%)      10 ( 4.7%)
                                   2                3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pneumonitis                  - Any Grade -     13 (12.0%)      0              13 ( 6.1%)
                                 Grade 1-2         11 (10.2%)      0              11 ( 5.2%)
                                   1                6 ( 5.6%)      0               6 ( 2.8%)
                                   2                5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Pleural effusion             - Any Grade -      5 ( 4.6%)      6 ( 5.8%)      11 ( 5.2%)
                                 Grade 1-2          2 ( 1.9%)      6 ( 5.8%)       8 ( 3.8%)
                                   1                0              3 ( 2.9%)       3 ( 1.4%)
                                   2                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 20 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Pulmonary embolism           - Any Grade -      6 ( 5.6%)      5 ( 4.8%)      11 ( 5.2%)
                                 Grade 1-2          4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                 Grade 3-4          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   3                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Interstitial lung disease    - Any Grade -      4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                 Grade 1-2          3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Oropharyngeal pain           - Any Grade -      5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
                                 Grade 1-2          5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Dysphonia                    - Any Grade -      3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                 Grade 1-2          3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                   1                3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
    Haemoptysis                  - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Dyspnoea exertional          - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Nasal congestion             - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Nasal dryness                - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Nasal inflammation           - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Respiratory failure          - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Allergic cough               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Alveolitis                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 21 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Bronchospasm                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Chronic obstructive          - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
    pulmonary disease
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Haemothorax                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Hiccups                      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hypoxia                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Lung opacity                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Nasal obstruction            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Painful respiration          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Pharyngeal inflammation      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Pleural thickening           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Pleuritic pain               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pneumothorax                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Productive cough             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Pulmonary fibrosis           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Pulmonary toxicity           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Rhinorrhoea                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 22 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Sputum discoloured           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Wheezing                     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  Nervous system disorders
    - Overall -                  - Any Grade -     55 (50.9%)     45 (43.3%)     100 (47.2%)
                                 Grade 1-2         50 (46.3%)     41 (39.4%)      91 (42.9%)
                                   1               39 (36.1%)     30 (28.8%)      69 (32.5%)
                                   2               11 (10.2%)     11 (10.6%)      22 (10.4%)
                                 Grade 3-4          5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                   3                5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
    Dysgeusia                    - Any Grade -     26 (24.1%)      9 ( 8.7%)      35 (16.5%)
                                 Grade 1-2         26 (24.1%)      9 ( 8.7%)      35 (16.5%)
                                   1               24 (22.2%)      9 ( 8.7%)      33 (15.6%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Paraesthesia                 - Any Grade -     14 (13.0%)      5 ( 4.8%)      19 ( 9.0%)
                                 Grade 1-2         14 (13.0%)      5 ( 4.8%)      19 ( 9.0%)
                                   1               11 (10.2%)      5 ( 4.8%)      16 ( 7.5%)
                                   2                3 ( 2.8%)      0               3 ( 1.4%)
    Headache                     - Any Grade -      8 ( 7.4%)     10 ( 9.6%)      18 ( 8.5%)
                                 Grade 1-2          8 ( 7.4%)     10 ( 9.6%)      18 ( 8.5%)
                                   1                8 ( 7.4%)      8 ( 7.7%)      16 ( 7.5%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Neuropathy peripheral        - Any Grade -      8 ( 7.4%)      9 ( 8.7%)      17 ( 8.0%)
                                 Grade 1-2          8 ( 7.4%)      7 ( 6.7%)      15 ( 7.1%)
                                   1                8 ( 7.4%)      6 ( 5.8%)      14 ( 6.6%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              2 ( 1.9%)       2 ( 0.9%)
                                   3                0              2 ( 1.9%)       2 ( 0.9%)
    Dizziness                    - Any Grade -      7 ( 6.5%)      9 ( 8.7%)      16 ( 7.5%)
                                 Grade 1-2          7 ( 6.5%)      9 ( 8.7%)      16 ( 7.5%)
                                   1                6 ( 5.6%)      5 ( 4.8%)      11 ( 5.2%)
                                   2                1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
    Sciatica                     - Any Grade -      8 ( 7.4%)      2 ( 1.9%)      10 ( 4.7%)
                                 Grade 1-2          8 ( 7.4%)      2 ( 1.9%)      10 ( 4.7%)
                                   1                7 ( 6.5%)      1 ( 1.0%)       8 ( 3.8%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Syncope                      - Any Grade -      3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   3                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 23 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Balance disorder             - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Peripheral sensory           - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
    neuropathy
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Ageusia                      - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Neurotoxicity                - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Polyneuropathy               - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
    Tremor                       - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Amnesia                      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Anosmia                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Brain oedema                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Carpal tunnel syndrome       - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Cognitive disorder           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Dysaesthesia                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Hypoaesthesia                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Hypogeusia                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 24 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Hypokinesia                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Intracranial pressure        - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
    increased
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Lethargy                     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Memory impairment            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Post herpetic neuralgia      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Seizure                      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Somnolence                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Taste disorder               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Transient ischaemic attack   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)

  Metabolism and nutrition
  disorders
    - Overall -                  - Any Grade -     53 (49.1%)     42 (40.4%)      95 (44.8%)
                                 Grade 1-2         40 (37.0%)     37 (35.6%)      77 (36.3%)
                                   1               24 (22.2%)     23 (22.1%)      47 (22.2%)
                                   2               16 (14.8%)     14 (13.5%)      30 (14.2%)
                                 Grade 3-4         13 (12.0%)      5 ( 4.8%)      18 ( 8.5%)
                                   3               12 (11.1%)      5 ( 4.8%)      17 ( 8.0%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Decreased appetite           - Any Grade -     20 (18.5%)     22 (21.2%)      42 (19.8%)
                                 Grade 1-2         19 (17.6%)     22 (21.2%)      41 (19.3%)
                                   1               10 ( 9.3%)     13 (12.5%)      23 (10.8%)
                                   2                9 ( 8.3%)      9 ( 8.7%)      18 ( 8.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 25 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Hypokalaemia                 - Any Grade -     10 ( 9.3%)      7 ( 6.7%)      17 ( 8.0%)
                                 Grade 1-2          8 ( 7.4%)      6 ( 5.8%)      14 ( 6.6%)
                                   1                6 ( 5.6%)      6 ( 5.8%)      12 ( 5.7%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   3                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Hypophosphataemia            - Any Grade -     11 (10.2%)      3 ( 2.9%)      14 ( 6.6%)
                                 Grade 1-2          8 ( 7.4%)      3 ( 2.9%)      11 ( 5.2%)
                                   1                4 ( 3.7%)      2 ( 1.9%)       6 ( 2.8%)
                                   2                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                 Grade 3-4          3 ( 2.8%)      0               3 ( 1.4%)
                                   3                3 ( 2.8%)      0               3 ( 1.4%)
    Hypocalcaemia                - Any Grade -      8 ( 7.4%)      4 ( 3.8%)      12 ( 5.7%)
                                 Grade 1-2          7 ( 6.5%)      4 ( 3.8%)      11 ( 5.2%)
                                   1                6 ( 5.6%)      2 ( 1.9%)       8 ( 3.8%)
                                   2                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Hypoalbuminaemia             - Any Grade -      6 ( 5.6%)      2 ( 1.9%)       8 ( 3.8%)
                                 Grade 1-2          5 ( 4.6%)      2 ( 1.9%)       7 ( 3.3%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Hyponatraemia                - Any Grade -      7 ( 6.5%)      1 ( 1.0%)       8 ( 3.8%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                   3                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
    Hyperglycaemia               - Any Grade -      2 ( 1.9%)      5 ( 4.8%)       7 ( 3.3%)
                                 Grade 1-2          1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                   1                1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Cell death                   - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Hyperkalaemia                - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 26 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Hypomagnesaemia              - Any Grade -      1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 1-2          1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                   1                1 ( 0.9%)      3 ( 2.9%)       4 ( 1.9%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Dehydration                  - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          0              2 ( 1.9%)       2 ( 0.9%)
                                   3                0              2 ( 1.9%)       2 ( 0.9%)
    Hyperphosphataemia           - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
    Hypertriglyceridaemia        - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Hyperuricaemia               - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Hypercholesterolaemia        - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Hypoglycaemia                - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Vitamin D deficiency         - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
    Diabetic metabolic           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    decompensation
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Hyperamylasaemia             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Hypercalcaemia               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hypernatraemia               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Hyperphosphatasaemia         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 27 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Increased appetite           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Iron deficiency              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Malnutrition                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)

  Musculoskeletal and
  connective tissue disorders
    - Overall -                  - Any Grade -     43 (39.8%)     41 (39.4%)      84 (39.6%)
                                 Grade 1-2         39 (36.1%)     37 (35.6%)      76 (35.8%)
                                   1               32 (29.6%)     21 (20.2%)      53 (25.0%)
                                   2                7 ( 6.5%)     16 (15.4%)      23 (10.8%)
                                 Grade 3-4          4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                   3                4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
    Back pain                    - Any Grade -     13 (12.0%)     14 (13.5%)      27 (12.7%)
                                 Grade 1-2         13 (12.0%)     11 (10.6%)      24 (11.3%)
                                   1                9 ( 8.3%)      7 ( 6.7%)      16 ( 7.5%)
                                   2                4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                 Grade 3-4          0              3 ( 2.9%)       3 ( 1.4%)
                                   3                0              3 ( 2.9%)       3 ( 1.4%)
    Arthralgia                   - Any Grade -     11 (10.2%)     15 (14.4%)      26 (12.3%)
                                 Grade 1-2         11 (10.2%)     15 (14.4%)      26 (12.3%)
                                   1               10 ( 9.3%)      6 ( 5.8%)      16 ( 7.5%)
                                   2                1 ( 0.9%)      9 ( 8.7%)      10 ( 4.7%)
    Myalgia                      - Any Grade -     15 (13.9%)     10 ( 9.6%)      25 (11.8%)
                                 Grade 1-2         13 (12.0%)     10 ( 9.6%)      23 (10.8%)
                                   1               13 (12.0%)      8 ( 7.7%)      21 ( 9.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Pain in extremity            - Any Grade -      9 ( 8.3%)      4 ( 3.8%)      13 ( 6.1%)
                                 Grade 1-2          9 ( 8.3%)      4 ( 3.8%)      13 ( 6.1%)
                                   1                7 ( 6.5%)      4 ( 3.8%)      11 ( 5.2%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Musculoskeletal chest pain   - Any Grade -      2 ( 1.9%)      7 ( 6.7%)       9 ( 4.2%)
                                 Grade 1-2          1 ( 0.9%)      7 ( 6.7%)       8 ( 3.8%)
                                   1                1 ( 0.9%)      6 ( 5.8%)       7 ( 3.3%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Bone pain                    - Any Grade -      4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                 Grade 1-2          4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                   1                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 28 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Muscle spasms                - Any Grade -      4 ( 3.7%)      0               4 ( 1.9%)
                                 Grade 1-2          4 ( 3.7%)      0               4 ( 1.9%)
                                   1                4 ( 3.7%)      0               4 ( 1.9%)
    Hypercreatinaemia            - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
    Muscular weakness            - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
    Osteoarthritis               - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Flank pain                   - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Intervertebral disc          - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
    protrusion
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Joint range of motion        - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    decreased
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Limb discomfort              - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Neck pain                    - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Osteonecrosis                - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Tendonitis                   - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Arthritis                    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Connective tissue disorder   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 29 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Foot deformity               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Groin pain                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Joint swelling               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Mobility decreased           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Muscle fatigue               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Muscle tightness             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Musculoskeletal discomfort   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Musculoskeletal disorder     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Myopathy                     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Osteoporosis                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Pain in jaw                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Pathological fracture        - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pubic pain                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Rheumatoid arthritis         - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Spinal pain                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 30 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  Skin and subcutaneous tissue
  disorders
    - Overall -                  - Any Grade -     45 (41.7%)     36 (34.6%)      81 (38.2%)
                                 Grade 1-2         45 (41.7%)     35 (33.7%)      80 (37.7%)
                                   1               37 (34.3%)     25 (24.0%)      62 (29.2%)
                                   2                8 ( 7.4%)     10 ( 9.6%)      18 ( 8.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Rash                         - Any Grade -     16 (14.8%)     12 (11.5%)      28 (13.2%)
                                 Grade 1-2         16 (14.8%)     11 (10.6%)      27 (12.7%)
                                   1               14 (13.0%)      8 ( 7.7%)      22 (10.4%)
                                   2                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Pruritus                     - Any Grade -      5 ( 4.6%)     10 ( 9.6%)      15 ( 7.1%)
                                 Grade 1-2          5 ( 4.6%)     10 ( 9.6%)      15 ( 7.1%)
                                   1                5 ( 4.6%)      8 ( 7.7%)      13 ( 6.1%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Alopecia                     - Any Grade -      7 ( 6.5%)      5 ( 4.8%)      12 ( 5.7%)
                                 Grade 1-2          7 ( 6.5%)      5 ( 4.8%)      12 ( 5.7%)
                                   1                6 ( 5.6%)      5 ( 4.8%)      11 ( 5.2%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Dry skin                     - Any Grade -      4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                 Grade 1-2          4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                   1                4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
    Hypertrichosis               - Any Grade -      7 ( 6.5%)      0               7 ( 3.3%)
                                 Grade 1-2          7 ( 6.5%)      0               7 ( 3.3%)
                                   1                6 ( 5.6%)      0               6 ( 2.8%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Erythema                     - Any Grade -      2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                 Grade 1-2          2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   1                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Hyperhidrosis                - Any Grade -      3 ( 2.8%)      0               3 ( 1.4%)
                                 Grade 1-2          3 ( 2.8%)      0               3 ( 1.4%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Night sweats                 - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Skin discolouration          - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Skin disorder                - Any Grade -      0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 1-2          0              3 ( 2.9%)       3 ( 1.4%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 31 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Dermatitis                   - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Eczema                       - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Erythrosis                   - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Nail dystrophy               - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Rash maculo-papular          - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Rosacea                      - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Seborrhoeic dermatitis       - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Skin exfoliation             - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Skin hyperpigmentation       - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
    Acne                         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Actinic keratosis            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Blister                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Cutaneous vasculitis         - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Decubitus ulcer              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Dermatitis acneiform         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 32 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Erythema multiforme          - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hyperkeratosis               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Nail bed bleeding            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Nail disorder                - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Nail ridging                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Onychalgia                   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Onychoclasis                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Onycholysis                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Palmar-plantar               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    erythrodysaesthesia
    syndrome
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Papule                       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Penile ulceration            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Rash papular                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Skin fissures                - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Skin irritation              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Stevens-Johnson syndrome     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 33 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  Vascular disorders
    - Overall -                  - Any Grade -     38 (35.2%)     16 (15.4%)      54 (25.5%)
                                 Grade 1-2         22 (20.4%)     13 (12.5%)      35 (16.5%)
                                   1               10 ( 9.3%)      4 ( 3.8%)      14 ( 6.6%)
                                   2               12 (11.1%)      9 ( 8.7%)      21 ( 9.9%)
                                 Grade 3-4         16 (14.8%)      3 ( 2.9%)      19 ( 9.0%)
                                   3               15 (13.9%)      3 ( 2.9%)      18 ( 8.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Hypertension                 - Any Grade -     33 (30.6%)      4 ( 3.8%)      37 (17.5%)
                                 Grade 1-2         19 (17.6%)      3 ( 2.9%)      22 (10.4%)
                                   1                7 ( 6.5%)      1 ( 1.0%)       8 ( 3.8%)
                                   2               12 (11.1%)      2 ( 1.9%)      14 ( 6.6%)
                                 Grade 3-4         14 (13.0%)      1 ( 1.0%)      15 ( 7.1%)
                                   3               13 (12.0%)      1 ( 1.0%)      14 ( 6.6%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Haematoma                    - Any Grade -      3 ( 2.8%)      3 ( 2.9%)       6 ( 2.8%)
                                 Grade 1-2          3 ( 2.8%)      3 ( 2.9%)       6 ( 2.8%)
                                   1                3 ( 2.8%)      0               3 ( 1.4%)
                                   2                0              3 ( 2.9%)       3 ( 1.4%)
    Hypotension                  - Any Grade -      4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                 Grade 1-2          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Thrombosis                   - Any Grade -      0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Deep vein thrombosis         - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Embolism                     - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Capillary fragility          - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hot flush                    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Lymphoedema                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 34 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Orthostatic hypertension     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Orthostatic hypotension      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Peripheral artery            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    thrombosis
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Thrombophlebitis migrans     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)

  Eye disorders
    - Overall -                  - Any Grade -     19 (17.6%)     21 (20.2%)      40 (18.9%)
                                 Grade 1-2         15 (13.9%)     21 (20.2%)      36 (17.0%)
                                   1               14 (13.0%)     17 (16.3%)      31 (14.6%)
                                   2                1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 3-4          4 ( 3.7%)      0               4 ( 1.9%)
                                   3                4 ( 3.7%)      0               4 ( 1.9%)
    Vision blurred               - Any Grade -      5 ( 4.6%)      5 ( 4.8%)      10 ( 4.7%)
                                 Grade 1-2          5 ( 4.6%)      5 ( 4.8%)      10 ( 4.7%)
                                   1                5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Lacrimation increased        - Any Grade -      0              7 ( 6.7%)       7 ( 3.3%)
                                 Grade 1-2          0              7 ( 6.7%)       7 ( 3.3%)
                                   1                0              6 ( 5.8%)       6 ( 2.8%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Dry eye                      - Any Grade -      0              4 ( 3.8%)       4 ( 1.9%)
                                 Grade 1-2          0              4 ( 3.8%)       4 ( 1.9%)
                                   1                0              3 ( 2.9%)       3 ( 1.4%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Eyelid oedema                - Any Grade -      3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                 Grade 1-2          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   1                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
    Periorbital oedema           - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Visual impairment            - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Eye pruritus                 - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 35 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Keratitis                    - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Ocular hyperaemia            - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Xerophthalmia                - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Blepharospasm                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Cataract                     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Corneal erosion              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Diplopia                     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Eye disorder                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Eye haemorrhage              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Eye pain                     - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Foreign body sensation in    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    eyes
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Noninfective conjunctivitis  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Periorbital swelling         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Scleral disorder             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Swelling of eyelid           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 36 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Ulcerative keratitis         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Visual acuity reduced        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)

  Renal and urinary disorders
    - Overall -                  - Any Grade -     22 (20.4%)     15 (14.4%)      37 (17.5%)
                                 Grade 1-2         15 (13.9%)     13 (12.5%)      28 (13.2%)
                                   1                8 ( 7.4%)      7 ( 6.7%)      15 ( 7.1%)
                                   2                7 ( 6.5%)      6 ( 5.8%)      13 ( 6.1%)
                                 Grade 3-4          7 ( 6.5%)      1 ( 1.0%)       8 ( 3.8%)
                                   3                7 ( 6.5%)      0               7 ( 3.3%)
                                   4                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Dysuria                      - Any Grade -      7 ( 6.5%)      2 ( 1.9%)       9 ( 4.2%)
                                 Grade 1-2          7 ( 6.5%)      2 ( 1.9%)       9 ( 4.2%)
                                   1                6 ( 5.6%)      1 ( 1.0%)       7 ( 3.3%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Acute kidney injury          - Any Grade -      5 ( 4.6%)      2 ( 1.9%)       7 ( 3.3%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          5 ( 4.6%)      0               5 ( 2.4%)
                                   3                5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Renal failure                - Any Grade -      3 ( 2.8%)      4 ( 3.8%)       7 ( 3.3%)
                                 Grade 1-2          2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
                                   4                0              1 ( 1.0%)       1 ( 0.5%)
    Urinary retention            - Any Grade -      4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                 Grade 1-2          3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Haematuria                   - Any Grade -      3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Chronic kidney disease       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 37 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Glycosuria                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hydronephrosis               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Leukocyturia                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Micturition urgency          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Nephritis                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Nephropathy toxic            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Proteinuria                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Renal cyst                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Renal impairment             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Renal vein thrombosis        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Strangury                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Urinary tract inflammation   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Urinary tract obstruction    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Urinary tract pain           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 38 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  No Coding available
    - Overall -                  - Any Grade -     23 (21.3%)      8 ( 7.7%)      31 (14.6%)
                                 Grade 1-2         23 (21.3%)      7 ( 6.7%)      30 (14.2%)
                                   1               13 (12.0%)      4 ( 3.8%)      17 ( 8.0%)
                                   2               10 ( 9.3%)      3 ( 2.9%)      13 ( 6.1%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    No Coding available          - Any Grade -     23 (21.3%)      8 ( 7.7%)      31 (14.6%)
                                 Grade 1-2         23 (21.3%)      7 ( 6.7%)      30 (14.2%)
                                   1               13 (12.0%)      4 ( 3.8%)      17 ( 8.0%)
                                   2               10 ( 9.3%)      3 ( 2.9%)      13 ( 6.1%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)

  Psychiatric disorders
    - Overall -                  - Any Grade -     16 (14.8%)     13 (12.5%)      29 (13.7%)
                                 Grade 1-2         14 (13.0%)     13 (12.5%)      27 (12.7%)
                                   1               11 (10.2%)     10 ( 9.6%)      21 ( 9.9%)
                                   2                3 ( 2.8%)      3 ( 2.9%)       6 ( 2.8%)
                                 Grade 3-4          2 ( 1.9%)      0               2 ( 0.9%)
                                   3                2 ( 1.9%)      0               2 ( 0.9%)
    Insomnia                     - Any Grade -      4 ( 3.7%)      7 ( 6.7%)      11 ( 5.2%)
                                 Grade 1-2          4 ( 3.7%)      7 ( 6.7%)      11 ( 5.2%)
                                   1                4 ( 3.7%)      5 ( 4.8%)       9 ( 4.2%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Anxiety                      - Any Grade -      5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                 Grade 1-2          5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                   1                4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Confusional state            - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Adjustment disorder with     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    depressed mood
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Agitation                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Depressed mood               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Depression                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 39 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Irritability                 - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Libido decreased             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Sleep disorder               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Suicide attempt              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)

  Injury, poisoning and
  procedural complications
    - Overall -                  - Any Grade -     13 (12.0%)     14 (13.5%)      27 (12.7%)
                                 Grade 1-2          8 ( 7.4%)     13 (12.5%)      21 ( 9.9%)
                                   1                6 ( 5.6%)      7 ( 6.7%)      13 ( 6.1%)
                                   2                2 ( 1.9%)      6 ( 5.8%)       8 ( 3.8%)
                                 Grade 3-4          5 ( 4.6%)      1 ( 1.0%)       6 ( 2.8%)
                                   3                4 ( 3.7%)      1 ( 1.0%)       5 ( 2.4%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Fall                         - Any Grade -      1 ( 0.9%)      5 ( 4.8%)       6 ( 2.8%)
                                 Grade 1-2          0              5 ( 4.8%)       5 ( 2.4%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Thermal burn                 - Any Grade -      0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Infusion related reaction    - Any Grade -      0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Joint dislocation            - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Rib fracture                 - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 40 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Skin abrasion                - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Ankle fracture               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Bone contusion               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Contusion                    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Femoral neck fracture        - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Femur fracture               - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Foot fracture                - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Foreign body in eye          - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Fracture displacement        - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Head injury                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Injury                       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Limb injury                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Pelvic fracture              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Peripancreatic fluid         - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    collection
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Procedural pain              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 41 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Radiation oedema             - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Stress fracture              - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Subdural haematoma           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Sunburn                      - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Vascular access site pain    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)

  Cardiac disorders
    - Overall -                  - Any Grade -      8 ( 7.4%)     17 (16.3%)      25 (11.8%)
                                 Grade 1-2          3 ( 2.8%)     13 (12.5%)      16 ( 7.5%)
                                   1                3 ( 2.8%)      8 ( 7.7%)      11 ( 5.2%)
                                   2                0              5 ( 4.8%)       5 ( 2.4%)
                                 Grade 3-4          3 ( 2.8%)      3 ( 2.9%)       6 ( 2.8%)
                                   3                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   4                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 5            2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Atrial fibrillation          - Any Grade -      2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                 Grade 1-2          1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Palpitations                 - Any Grade -      0              4 ( 3.8%)       4 ( 1.9%)
                                 Grade 1-2          0              4 ( 3.8%)       4 ( 1.9%)
                                   1                0              4 ( 3.8%)       4 ( 1.9%)
    Tachycardia                  - Any Grade -      0              4 ( 3.8%)       4 ( 1.9%)
                                 Grade 1-2          0              4 ( 3.8%)       4 ( 1.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Angina pectoris              - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Cardiac tamponade            - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   4                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 42 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Pericardial effusion         - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   4                1 ( 0.9%)      0               1 ( 0.5%)
    Acute myocardial infarction  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Bradycardia                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Cardio-respiratory arrest    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 5            1 ( 0.9%)      0               1 ( 0.5%)
    Myocardial infarction        - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 5            0              1 ( 1.0%)       1 ( 0.5%)
    Myocarditis                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   4                0              1 ( 1.0%)       1 ( 0.5%)
    Pericarditis                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Restrictive cardiomyopathy   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Sinus bradycardia            - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Ventricular extrasystoles    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)

  Hepatobiliary disorders
    - Overall -                  - Any Grade -     11 (10.2%)     14 (13.5%)      25 (11.8%)
                                 Grade 1-2          7 ( 6.5%)      9 ( 8.7%)      16 ( 7.5%)
                                   1                6 ( 5.6%)      7 ( 6.7%)      13 ( 6.1%)
                                   2                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 3-4          4 ( 3.7%)      5 ( 4.8%)       9 ( 4.2%)
                                   3                4 ( 3.7%)      5 ( 4.8%)       9 ( 4.2%)
    Hypertransaminasaemia        - Any Grade -      5 ( 4.6%)      7 ( 6.7%)      12 ( 5.7%)
                                 Grade 1-2          5 ( 4.6%)      6 ( 5.8%)      11 ( 5.2%)
                                   1                5 ( 4.6%)      4 ( 3.8%)       9 ( 4.2%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 43 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Hepatic cytolysis            - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Hepatotoxicity               - Any Grade -      0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Cholangitis                  - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Cholecystitis                - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   3                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
    Hyperbilirubinaemia          - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Drug-induced liver injury    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Hepatic artery thrombosis    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Hepatic failure              - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hepatitis                    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Liver disorder               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)

  Ear and labyrinth disorders
    - Overall -                  - Any Grade -     10 ( 9.3%)      8 ( 7.7%)      18 ( 8.5%)
                                 Grade 1-2         10 ( 9.3%)      8 ( 7.7%)      18 ( 8.5%)
                                   1                8 ( 7.4%)      8 ( 7.7%)      16 ( 7.5%)
                                   2                2 ( 1.9%)      0               2 ( 0.9%)
    Vertigo                      - Any Grade -      4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                 Grade 1-2          4 ( 3.7%)      4 ( 3.8%)       8 ( 3.8%)
                                   1                3 ( 2.8%)      4 ( 3.8%)       7 ( 3.3%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 44 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Tinnitus                     - Any Grade -      3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                 Grade 1-2          3 ( 2.8%)      2 ( 1.9%)       5 ( 2.4%)
                                   1                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Ear pain                     - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Deafness bilateral           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    External ear pain            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Hypoacusis                   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)

  Reproductive system and
  breast disorders
    - Overall -                  - Any Grade -     11 (10.2%)      3 ( 2.9%)      14 ( 6.6%)
                                 Grade 1-2         10 ( 9.3%)      3 ( 2.9%)      13 ( 6.1%)
                                   1                9 ( 8.3%)      2 ( 1.9%)      11 ( 5.2%)
                                   2                1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Erectile dysfunction         - Any Grade -      5 ( 4.6%)      0               5 ( 2.4%)
                                 Grade 1-2          5 ( 4.6%)      0               5 ( 2.4%)
                                   1                4 ( 3.7%)      0               4 ( 1.9%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Vaginal haemorrhage          - Any Grade -      2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                 Grade 1-2          2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
                                   1                2 ( 1.9%)      1 ( 1.0%)       3 ( 1.4%)
    Pelvic pain                  - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Adnexa uteri cyst            - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Benign prostatic             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
    hyperplasia
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Prostatic disorder           - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 45 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Prostatitis                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  Endocrine disorders
    - Overall -                  - Any Grade -      3 ( 2.8%)     10 ( 9.6%)      13 ( 6.1%)
                                 Grade 1-2          3 ( 2.8%)      9 ( 8.7%)      12 ( 5.7%)
                                   1                2 ( 1.9%)      2 ( 1.9%)       4 ( 1.9%)
                                   2                1 ( 0.9%)      7 ( 6.7%)       8 ( 3.8%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Hypothyroidism               - Any Grade -      3 ( 2.8%)      9 ( 8.7%)      12 ( 5.7%)
                                 Grade 1-2          3 ( 2.8%)      8 ( 7.7%)      11 ( 5.2%)
                                   1                2 ( 1.9%)      4 ( 3.8%)       6 ( 2.8%)
                                   2                1 ( 0.9%)      4 ( 3.8%)       5 ( 2.4%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Hyperthyroidism              - Any Grade -      0              3 ( 2.9%)       3 ( 1.4%)
                                 Grade 1-2          0              3 ( 2.9%)       3 ( 1.4%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              2 ( 1.9%)       2 ( 0.9%)
    Hypophysitis                 - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)

  Neoplasms benign, malignant
  and unspecified (incl cysts
  and polyps)
    - Overall -                  - Any Grade -      6 ( 5.6%)      6 ( 5.8%)      12 ( 5.7%)
                                 Grade 1-2          4 ( 3.7%)      3 ( 2.9%)       7 ( 3.3%)
                                   1                3 ( 2.8%)      1 ( 1.0%)       4 ( 1.9%)
                                   2                1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 3-4          2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
                                   3                2 ( 1.9%)      3 ( 2.9%)       5 ( 2.4%)
    Anogenital warts             - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                2 ( 1.9%)      0               2 ( 0.9%)
    Cancer pain                  - Any Grade -      1 ( 0.9%)      1 ( 1.0%)       2 ( 0.9%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Anal cancer                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Endometrial adenocarcinoma   - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 46 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

    Lipoma                       - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Neoplasm                     - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
    Non-small cell lung cancer   - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Paraneoplastic syndrome      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)
    Skin papilloma               - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   2                0              1 ( 1.0%)       1 ( 0.5%)
    Tumour pain                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 3-4          0              1 ( 1.0%)       1 ( 0.5%)
                                   3                0              1 ( 1.0%)       1 ( 0.5%)

  Immune system disorders
    - Overall -                  - Any Grade -      1 ( 0.9%)      2 ( 1.9%)       3 ( 1.4%)
                                 Grade 1-2          0              2 ( 1.9%)       2 ( 0.9%)
                                   1                0              2 ( 1.9%)       2 ( 0.9%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Contrast media reaction      - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Drug hypersensitivity        - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Immune system disorder       - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)

  Surgical and medical
  procedures
    - Overall -                  - Any Grade -      2 ( 1.9%)      0               2 ( 0.9%)
                                 Grade 1-2          2 ( 1.9%)      0               2 ( 0.9%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Abdominal cavity drainage    - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   2                1 ( 0.9%)      0               1 ( 0.5%)
    Tooth extraction             - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 1-2          1 ( 0.9%)      0               1 ( 0.5%)
                                   1                1 ( 0.9%)      0               1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 47 of 48

Adverse Events by System Organ Class and Preferred Term and by Highest NCI CTCAE Grade - Main
Treatment Period, Safety-Evaluable Patients
Protocol: BO42864
  ___________________________________________________________________________________________

  MedDRA System Organ Class                       Pralsetinib  Standard of Care  All Patients
    MedDRA Preferred Term        Grade              (N=108)        (N=104)         (N=212)
  ___________________________________________________________________________________________

  Congenital, familial and
  genetic disorders
    - Overall -                  - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)
    Hydrocele                    - Any Grade -      0              1 ( 1.0%)       1 ( 0.5%)
                                 Grade 1-2          0              1 ( 1.0%)       1 ( 0.5%)
                                   1                0              1 ( 1.0%)       1 ( 0.5%)

  Product issues
    - Overall -                  - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)
    Device dislocation           - Any Grade -      1 ( 0.9%)      0               1 ( 0.5%)
                                 Grade 3-4          1 ( 0.9%)      0               1 ( 0.5%)
                                   3                1 ( 0.9%)      0               1 ( 0.5%)

  ___________________________________________________________________________________________
  Investigator text for AEs encoded using MedDRA version 27.0.  All counts represent
  patients. Multiple occurrences of the same AE in one individual are counted once at the
  highest grade for this patient.
  To the SOC Overall row counts, a patient contributes only with the AE occuring with the
  highest grade within the SOC.
  Percentages are based on N in the column headings.
  AEs with onset during the cross-over period are not displayed in this output.

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
         program/t_ae_ctc.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/
        output/t_ae_ctc_MAIN_SE.out
18JUL2024 16:35                                                                 Page 48 of 48

Listing of Baseline Neutrophil and Lymphocyte Lab Values and Medical History of Neutropenia and Lymphopenia events for Patients with
Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
  Treatment: Pralsetinib (N=108)

  ____________________________________________________________________________________________________________

                                                                          Reference  Reference  History of
  Center/Patient ID - Age/Sex/Race                             Standard     Range      Range    Neutropenia
    Lab Test Name                   Visit Name     Lab Result  Lab Units     Low       High     or Lymphopenia
  ____________________________________________________________________________________________________________

  3301/008 - 67/F/Asian
    Lymphocytes                     CYCLE 1 DAY 1  D
    Neutrophils                     CYCLE 1 DAY 1  5.78        10^9/L       1.8        7.8
  3302/004 - 71/M/Asian
    Lymphocytes                     SCREENING      0.71        10^9/L       1.1        4.1
    Neutrophils                     SCREENING      6.12        10^9/L       1.7        7
  3302/005 - 74/M/Asian
    Lymphocytes                     CYCLE 1 DAY 1  1.73        10^9/L       1.1        4.1
    Neutrophils                     CYCLE 1 DAY 1  5.35        10^9/L       1.7        7
  3302/007 - 52/F/Asian
    Lymphocytes                     SCREENING      1.02        10^9/L       1.1        4.1
    Neutrophils                     SCREENING      8.57        10^9/L       1.6        7
  3302/012 - 57/M/Asian
    Lymphocytes                     SCREENING      2.3         10^9/L       1.1        4.1
    Neutrophils                     SCREENING      5.26        10^9/L       1.7        7
  3302/013 - 67/F/Asian
    Lymphocytes                     CYCLE 1 DAY 1  1.98        10^9/L       1.1        4.1
    Neutrophils                     CYCLE 1 DAY 1  9.44        10^9/L       1.6        7
  4201/002 - 76/F/Unknown
    Lymphocytes                     SCREENING      2.1         10^9/L       1          4
    Neutrophils                     SCREENING      4.47        10^9/L       1.8        7.5
  4202/001 - 77/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.36        10^9/L       1.5        4
    Neutrophils                     CYCLE 1 DAY 1  6.86        10^9/L       1.5        7
  4206/001 - 71/F/NOT REPORTED
    Lymphocytes                     CYCLE 1 DAY 1  2.25        10^9/L       1          4
    Neutrophils                     CYCLE 1 DAY 1  4.05        10^9/L       1.8        7.5
  4208/004 - 73/F/Other
    Lymphocytes                     CYCLE 1 DAY 1  2.1         10^9/L       1.2        4
    Neutrophils                     CYCLE 1 DAY 1  4.5         10^9/L       1.5        7
  ____________________________________________________________________________________________________________
  Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_inf3_SE_12JUL2024_42864.out
16OCT2024 17:11                                                                                                            Page 1 of 4

Listing of Baseline Neutrophil and Lymphocyte Lab Values and Medical History of Neutropenia and Lymphopenia events for Patients with
Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
  Treatment: Pralsetinib (N=108)

  ____________________________________________________________________________________________________________

                                                                          Reference  Reference  History of
  Center/Patient ID - Age/Sex/Race                             Standard     Range      Range    Neutropenia
    Lab Test Name                   Visit Name     Lab Result  Lab Units     Low       High     or Lymphopenia
  ____________________________________________________________________________________________________________

  4307/004 - 59/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.53        10^9/L       1.5        4
    Neutrophils                     CYCLE 1 DAY 1  5.4         10^9/L       1.8        7.55
  4404/003 - 57/M/White
    Lymphocytes                     CYCLE 1 DAY 1  2.07        10^9/L       1.1        4.5
    Neutrophils                     CYCLE 1 DAY 1  4.25        10^9/L       1.5        7.7
  4404/005 - 53/M/White
    Lymphocytes                     CYCLE 1 DAY 1  1.69        10^9/L       1.1        4.5
    Neutrophils                     CYCLE 1 DAY 1  5.52        10^9/L       1.5        7.7
  4404/011 - 71/M/White
    Lymphocytes                     CYCLE 1 DAY 1  1.41        10^9/L       1.1        4
    Neutrophils                     CYCLE 1 DAY 1  4.86        10^9/L       1.5        7.7
  4406/003 - 53/M/White
    Lymphocytes                     CYCLE 1 DAY 1  0.7         10^9/L       1          4.8
    Neutrophils                     CYCLE 1 DAY 1  5.7         10^9/L       1.8        7.7
  4410/008 - 65/M/White
    Lymphocytes                     CYCLE 1 DAY 1  1.82        10^9/L       1.13       3.37
    Neutrophils                     CYCLE 1 DAY 1  3.88        10^9/L       1.81       6.74
  4508/002 - 79/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.7         10^9/L       1.2        3.5
    Neutrophils                     CYCLE 1 DAY 1  13.8        10^9/L       2          7
  4508/003 - 72/M/White
    Lymphocytes                     CYCLE 1 DAY 1  6.6         10^9/L       1.2        3.5
    Neutrophils                     CYCLE 1 DAY 1  6.7         10^9/L       2          7
  4517/001 - 58/M/White
    Lymphocytes                     SCREENING      1.77        10^9/L       1.2        3.4
    Neutrophils                     SCREENING      2.95        10^9/L       1.5        7.5
  4601/001 - 61/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.29        10^9/L       1.5        4
    Neutrophils                     CYCLE 1 DAY 1  4.99        10^9/L       1.4        8
  ____________________________________________________________________________________________________________
  Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_inf3_SE_12JUL2024_42864.out
16OCT2024 17:11                                                                                                            Page 2 of 4

Listing of Baseline Neutrophil and Lymphocyte Lab Values and Medical History of Neutropenia and Lymphopenia events for Patients with
Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
  Treatment: Pralsetinib (N=108)

  ____________________________________________________________________________________________________________

                                                                          Reference  Reference  History of
  Center/Patient ID - Age/Sex/Race                             Standard     Range      Range    Neutropenia
    Lab Test Name                   Visit Name     Lab Result  Lab Units     Low       High     or Lymphopenia
  ____________________________________________________________________________________________________________

  4601/003 - 68/F/White
    Lymphocytes                     SCREENING      0.57        10^9/L       1.5        4
    Neutrophils                     SCREENING      4           10^9/L       1.4        8
  4701/001 - 33/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.1         10^9/L       1.5        4
    Neutrophils                     CYCLE 1 DAY 1  12.3        10^9/L       2          7.5
  4703/002 - 51/F/Unknown
    Lymphocytes                     CYCLE 1 DAY 1  3.1         10^9/L       1.2        3.5
    Neutrophils                     CYCLE 1 DAY 1  17.4        10^9/L       1.5        7
  4801/002 - 54/F/White
    Lymphocytes                     CYCLE 1 DAY 1  0.8         10^9/L       1.5        3.5
    Neutrophils                     CYCLE 1 DAY 1  12.6        10^9/L       2          7.5
  7201/001 - 70/F/American Indian or Alaska Native
    Lymphocytes                     SCREENING      1.15        10^9/L       1          5
    Neutrophils                     SCREENING      15.64       10^9/L       2.5        7.725
  7301/006 - 64/M/American Indian or Alaska Native
    Lymphocytes                     CYCLE 1 DAY 1  1.45        10^9/L       0.9        2.9
    Neutrophils                     CYCLE 1 DAY 1  6.49        10^9/L       1.7        7
  7301/012 - 65/F/American Indian or Alaska Native
    Lymphocytes                     SCREENING      0.37        10^9/L       0.9        2.9
    Neutrophils                     SCREENING      2.08        10^9/L       1.7        7
  8411/001 - 75/M/Asian
    Lymphocytes                     SCREENING      1.305       10^9/L       1          5
    Neutrophils                     SCREENING      4.147       10^9/L       1          8
  ____________________________________________________________________________________________________________
  Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_inf3_SE_12JUL2024_42864.out
16OCT2024 17:11                                                                                                            Page 3 of 4

Listing of Baseline Neutrophil and Lymphocyte Lab Values and Medical History of Neutropenia and Lymphopenia events for Patients with
Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
  Treatment: Standard of Care (N=104)

  ____________________________________________________________________________________________________________

                                                                          Reference  Reference  History of
  Center/Patient ID - Age/Sex/Race                             Standard     Range      Range    Neutropenia
    Lab Test Name                   Visit Name     Lab Result  Lab Units     Low       High     or Lymphopenia
  ____________________________________________________________________________________________________________

  4404/007 - 48/M/White
    Lymphocytes                     CYCLE 1 DAY 1  0.94        10^9/L       1.1        4.5
    Neutrophils                     CYCLE 1 DAY 1  6.26        10^9/L       1.5        7.7
  4503/001 - 63/F/White
    Lymphocytes                     CYCLE 1 DAY 1  1.6         10^9/L       1.1        3.5
    Neutrophils                     CYCLE 1 DAY 1  6.58        10^9/L       1.8        7.4
  4505/002 - 83/F/White
    Lymphocytes                     SCREENING      0.5         10^9/L       1.3        3.5
    Neutrophils                     SCREENING      2.5         10^9/L       1.8        7.5
  4508/001 - 64/F/White
    Lymphocytes                     SCREENING      0.8         10^9/L       1.2        3.5
    Neutrophils                     SCREENING      6.4         10^9/L       2          7
  4512/002 - 70/M/White
    Lymphocytes                     CYCLE 1 DAY 1  2.1         10^9/L       1.2        5
    Neutrophils                     CYCLE 1 DAY 1  5.3         10^9/L       1.4        7.5
  4706/001 - 74/M/Other
    Lymphocytes                     CYCLE 1 DAY 1  1           10^9/L       1          4.5
    Neutrophils                     CYCLE 1 DAY 1  7.3         10^9/L       1.7        7.5
  5203/003 - 74/M/White
    Lymphocytes                     CYCLE 1 DAY 1
    Neutrophils                     CYCLE 1 DAY 1  2.8         10^9/L       1.4        7.7
  8001/003 - 43/M/Asian
    Lymphocytes                     SCREENING      1           10^9/L       1          4
    Neutrophils                     SCREENING      7.3         10^9/L       2          8
  ____________________________________________________________________________________________________________
  Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_inf3_SE_12JUL2024_42864.out
16OCT2024 17:11                                                                                                            Page 4 of 4

Listing of Prior and Concomitant Corticosteroids in Patients with Severe Opportunistic Infections
Protocol: BO42864
Snapshot date: 12th July 2024
  Treatment: Pralsetinib (N=108)

  _________________________________________________________________________________________________________________________________________________________

                                                                            Study  Study
  Center/Patient ID - Age/Sex/Race                  Medication  Medication  Start   End                           Route of
    Medication Name                                 Start Date   End Date    Day    Day   Dose  Frequency         Administration            Indication
  _________________________________________________________________________________________________________________________________________________________

  3301/008 - 67/F/Asian
    METHYLPREDNISOLONE                              09JAN2024   17JAN2024     85     93         QD                INTRAVENOUS               ADVERSE EVENT
    PREDNISOLONE                                    18JAN2024   27JAN2024     94    103         QD                ORAL                      ADVERSE EVENT

  3302/007 - 52/F/Asian
    PREDNISOLONE                                    19MAY2022   27MAY2022    178    186         QD                ORAL                      ADVERSE EVENT
    METHYLPREDNISOLONE SODIUM SUCCINATE             27MAY2022   31MAY2022    186    190         BID               INTRAVENOUS               ADVERSE EVENT
    METHYLPREDNISOLONE SODIUM SUCCINATE             20JUN2022   21JUN2022    210    211         QD                INTRAVENOUS               ADVERSE EVENT
    METHYLPREDNISOLONE SODIUM SUCCINATE             22JUN2022   27JUN2022    212    217         BID               INTRAVENOUS               ADVERSE EVENT
    METHYLPREDNISOLONE SODIUM SUCCINATE             28JUN2022   30JUN2022    218    220         QD                INTRAVENOUS               ADVERSE EVENT
    METHYLPREDNISOLONE SODIUM SUCCINATE             30JUN2022   05JUL2022    220    225         BID               INTRAVENOUS               ADVERSE EVENT

  4517/001 - 58/M/White
    BECLOMETASONE DIPROPIONATE;FORMOTEROL FUMARATE  01JUN2020   17MAY2021   -143    208         QD                RESPIRATORY (INHALATION)  MEDICAL HISTORY
    BUDESONIDE                                      06DEC2020   09DEC2020     46     49         PRN               RESPIRATORY (INHALATION)  ADVERSE EVENT
    BUDESONIDE                                      17MAR2021   20MAR2021    147    150         BID               RESPIRATORY (INHALATION)  ADVERSE EVENT
    DEXAMETHASONE                                   24JUN2021   24JUN2021    246    246         QD                INTRAVENOUS               ADVERSE EVENT
    PREDNISONE                                      25JUN2021   08AUG2021    247    291         QD                ORAL                      ADVERSE EVENT
    BUDESONIDE                                      30NOV2021   31DEC2021    405    436         BID               NASAL                     ADVERSE EVENT
    METHYLPREDNISOLONE                              30NOV2021   01DEC2021    405    406         TID               INTRAVENOUS               ADVERSE EVENT
    PREDNISONE                                      01DEC2021   03DEC2021    406    408         QD                INTRAVENOUS               ADVERSE EVENT

  4801/002 - 54/F/White
    FLUTICASONE FUROATE;VILANTEROL TRIFENATATE      01DEC2021                -68*               QD                RESPIRATORY (INHALATION)  MEDICAL HISTORY
    FLUTICASONE FUROATE                             01JAN2022                -37*               PRN               NASAL                     MEDICAL HISTORY
    DEXAMETHASONE                                   18JAN2022                -20                QD                ORAL                      MEDICAL HISTORY
    DEXAMETHASONE                                   11APR2022   19APR2022     64     72         BID               INTRAVENOUS               ADVERSE EVENT
    DEXAMETHASONE                                   21APR2022   22APR2022     74     75         QD                ORAL                      ADVERSE EVENT

  7301/006 - 64/M/American Indian or Alaska Native
    CICLESONIDE                                     29OCT2022   17DEC2023    -39    376         QD                RESPIRATORY (INHALATION)  MEDICAL HISTORY
    PREDNISONE                                      08MAY2023   17MAY2023    153    162         QD                ORAL                      ADVERSE EVENT
    BUDESONIDE                                      06SEP2023                274                BID               RESPIRATORY (INHALATION)  ADVERSE EVENT

  8411/001 - 75/M/Asian
    METHYLPREDNISOLONE SODIUM SUCCINATE             26OCT2022   28OCT2022     69     71         QD                IV                        ADVERSE EVENT
    PREDNISOLONE                                    29OCT2022   14NOV2022     72     88         QD                IV                        ADVERSE EVENT
    PREDNISOLONE                                    15NOV2022   23DEC2022     89    127         QD                ORAL                      ADVERSE EVENT

  _________________________________________________________________________________________________________________________________________________________
  * Study day derived from imputed medication start date.
  Patients with only Opportunistic Infections AEs with onset during the cross-over period are not considered in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_cm_oppinf.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_cm_oppinf_SE_12JUL2024_42864.out
16OCT2024 17:08                                                                                                                                                          Page 1 of 1

Listing of Neutropenia and Lymphopenia events for Patients with Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
    Treatment: Pralsetinib (N=108)

    ______________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race                                                           Most
      Adverse Event MedDRA            Date of First   Study       AE                           Extreme
      System Organ Class                Study Drug    Day of  Duration in  Crossover           CTCAE    Caused by                Action
        Preferred Term                Administration  Onset      Days      phase      Serious  Grade    Study Drug  Outcome (1)  Taken (2)
    ______________________________________________________________________________________________________________________________________

  3302/004 - 71/M/Asian
    Investigations
      Neutrophil count decreased        27APR2021      262                 No         No       4        No          2            6

  3302/007 - 52/F/Asian
    Investigations
      Lymphocyte count decreased        23NOV2021       44       21        No         No       2        Yes         3            2

  4201/002 - 76/F/Unknown
    Blood and lymphatic system disorders
      Lymphopenia                       03MAY2023       21        5        No         No       1        Yes         3            2

  4202/001 - 77/F/White
    Investigations
      Neutrophil count decreased        12MAY2021       20       10        No         No       3        Yes         3            3

  4208/004 - 73/F/Other
    Blood and lymphatic system disorders
      Lymphopenia                       08NOV2022       86       28**      No         No       1        Yes         3            2

  4307/004 - 59/F/White
    Investigations
      Neutrophil count decreased        21APR2021       21       43        No         No       3        Yes         3            3
    Investigations
      Neutrophil count decreased        21APR2021       85       41        No         No       2        Yes         3            2
    Investigations
      Neutrophil count decreased        21APR2021      126       28        No         No       1        Yes         3            2
    Investigations
      Neutrophil count decreased        21APR2021      154       22        No         No       2        Yes         3            2
    Investigations
      Neutrophil count decreased        21APR2021      301       21        No         No       2        Yes         3            2
    Investigations
      Neutrophil count decreased        21APR2021      343       64        No         No       2        Yes         3            2
    ______________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (2) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date
    Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_inf3_NEULYMPH_SE_12JUL2024_42864.out
16OCT2024 17:14                                                                                                                                                          Page 1 of 4

Listing of Neutropenia and Lymphopenia events for Patients with Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
    Treatment: Pralsetinib (N=108)

    ______________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race                                                           Most
      Adverse Event MedDRA            Date of First   Study       AE                           Extreme
      System Organ Class                Study Drug    Day of  Duration in  Crossover           CTCAE    Caused by                Action
        Preferred Term                Administration  Onset      Days      phase      Serious  Grade    Study Drug  Outcome (1)  Taken (2)
    ______________________________________________________________________________________________________________________________________

  4404/003 - 57/M/White
    Blood and lymphatic system disorders
      Neutropenia                       23DEC2020       23       22        No         No       2        Yes         3            2
    Blood and lymphatic system disorders
      Neutropenia                       23DEC2020       86                 No         No       2        Yes         5            2

  4404/005 - 53/M/White
    Blood and lymphatic system disorders
      Neutropenia                       14APR2021      434                 No         No       3        Yes         5            2

  4410/008 - 65/M/White
    Blood and lymphatic system disorders
      Neutropenia                       06MAR2023      117        8        No         No       3        Yes         3            4
    Blood and lymphatic system disorders
      Neutropenia                       06MAR2023      169       22        No         No       2        Yes         3            2

  4517/001 - 58/M/White
    Blood and lymphatic system disorders
      Neutropenia                       22OCT2020      161        7        No         No       3        No          3            2
    Blood and lymphatic system disorders
      Neutropenia                       22OCT2020      610       26        No         No       2        Yes         3            4

  4801/002 - 54/F/White
    Investigations
      Neutrophil count decreased        07FEB2022      218       22        No         No       2        No          3            2
    Investigations
      Neutrophil count decreased        07FEB2022      242       14        No         No       3        No          3            2
    Investigations
      Neutrophil count decreased        07FEB2022      247        9        No         No       3        No          3            2
    Investigations
      Neutrophil count decreased        07FEB2022      372       22        No         No       2        No          3            2

    ______________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (2) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date
    Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_inf3_NEULYMPH_SE_12JUL2024_42864.out
16OCT2024 17:14                                                                                                                                                          Page 2 of 4

Listing of Neutropenia and Lymphopenia events for Patients with Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
    Treatment: Pralsetinib (N=108)

    ______________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race                                                           Most
      Adverse Event MedDRA            Date of First   Study       AE                           Extreme
      System Organ Class                Study Drug    Day of  Duration in  Crossover           CTCAE    Caused by                Action
        Preferred Term                Administration  Onset      Days      phase      Serious  Grade    Study Drug  Outcome (1)  Taken (2)
    ______________________________________________________________________________________________________________________________________

  7201/001 - 70/F/American Indian or Alaska Native
    Blood and lymphatic system disorders
      Lymphopenia                       11JUL2022       22                 No         No       3        Yes         5            4

  8411/001 - 75/M/Asian
    Investigations
      Neutrophil count decreased        19AUG2022       22       13        No         No       2        Yes         3            2

    ______________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (2) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date
    Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_inf3_NEULYMPH_SE_12JUL2024_42864.out
16OCT2024 17:14                                                                                                                                                          Page 3 of 4

Listing of Neutropenia and Lymphopenia events for Patients with Grade 3-5 Infections
Protocol: BO42864
Snapshot date: 12th July 2024
    Treatment: Standard of Care (N=104)

    ______________________________________________________________________________________________________________________________________

    Center/Patient ID - Age/Sex/Race                                                           Most
      Adverse Event MedDRA            Date of First   Study       AE                           Extreme
      System Organ Class                Study Drug    Day of  Duration in  Crossover           CTCAE    Caused by                Action
        Preferred Term                Administration  Onset      Days      phase      Serious  Grade    Study Drug  Outcome (1)  Taken (2)
    ______________________________________________________________________________________________________________________________________

  4503/001 - 63/F/White
    Blood and lymphatic system disorders
      Lymphopenia                       09MAR2023       22                 No         No       2        Yes         5            2

  4505/002 - 83/F/White
    Investigations
      Neutrophil count decreased        09JUN2022       22        8        No         No       1        Yes         3            4
    Investigations
      Neutrophil count decreased        09JUN2022       50        7        No         No       3        Yes         3            4
    Investigations
      Neutrophil count decreased        09JUN2022       78       15        No         No       2        Yes         3            3
    Investigations
      Neutrophil count decreased        09JUN2022      134       29        No         No       2        Yes         3            4

  4512/002 - 70/M/White
    Blood and lymphatic system disorders
      Neutropenia                       03MAY2022       53       25        No         No       3        Yes         3            4

    ______________________________________________________________________________________________________________________________________
    Notes: Adverse Events are coded using MedDRA 27.0
    For patients who crossed over, date of first Study Drug Administration is provided for the standard of care treatment in the main treatment period and for Pralsetinb in the
    crossover treatment period.
    (1) Outcome: 1 = fatal; 2 = not recovered/not resolved; 3 = recovered/resolved; 4 = recovered/resolved with sequelae; 5 = recovering/resolving; 6 = unknown.
    (2) Action taken: 1 = dose increased; 2 = dose not changed; 3 = dose reduced; 4 = drug interrupted; 5 = drug withdrawn; 6 = not applicable; 7 = unknown.
    *  Study day derived from imputed onset date
    ** Duration derived from imputed onset date and/or end date
    Patients with Grade 3-5 Infections during the main period of treatment are included in this output

Program: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/program/l_ae_inf3.sas
Output: root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_inf3_NEULYMPH_SE_12JUL2024_42864.out
16OCT2024 17:14                                                                                                                                                          Page 4 of 4

68
Drug Safety Report No: 1132062
Appendix 2
Overview of Subjects with Grade 3 and 4 Infections in
AcceleRET-Lung study
The below Table presents an overview of Subjects with Grade 3 and Grade 4 Infections
in Pralsetinib Treatment Arm of the AcceleRET-Lung study (N=23)
Patient number
Age/Sex
Ethnicity/Country
Indication
MedDRA PT (Grading)
Time to Event Onset (in days)
Outcome
Action taken with Pralsetinib
Causality (as per
investigator)
3301/008
67/Female
Asian/ Korea, Republic Of
Non-small cell lung cancer
Pneumonia cytomegaloviral
(Grade 3)
SD 85
Resolved
Drug interrupted
Related
3302/004
71/ Male
Asian/ Korea, republic Of
Small cell lung cancer
Pleural infection (Grade 3)
SD 204
Resolved
Device related infection (Grade 3)
SD 214
Resolved
Drug interrupted
Not related
Dose not changed
Not related
3302/005
74/Male
Asian/ Korea, republic Of
Non-small cell lung cancer
Pneumonia (Grade 3)
SD 65
Not resolved
Drug withdrawn
Not related
3302/007
52/Female
Asian/ Korea, republic Of
Non-small cell lung cancer
metastatic
Pneumocystis jirovecii pneumonia
(Grade 3)
SD 161
Resolved with sequelae
Pneumonia cytomegaloviral
(Grade 3)
SD 161
Not resolved
Drug interrupted
Not related
Drug withdrawn
Not related
3302/013
67/Female
Asian// Korea, republic Of
Non-small cell lung cancer
metastatic
Pneumonia (Grade 3)
SD 67
Resolved
Pyelonephritis acute (Grade 3)
SD 67
Resolved
Drug interrupted
Not related
Drug interrupted
Not related

69
Drug Safety Report No: 1132062
Patient number
Age/Sex
Ethnicity/Country
Indication
MedDRA PT (Grading)
Time to Event Onset (in days)
Outcome
Action taken with Pralsetinib
Causality (as per
investigator)
4202/001
77/Female
White/ France
Non-small cell lung cancer
Staphylococcal sepsis (Grade 3)
SD 290
Resolved
Dose not changed
Not related
4206/001
71/Female
Unknown/ France
Non-small cell lung cancer
Pyelonephritis (Grade 3)
SD 48
Resolved
Pyelonephritis (Grade 3)
SD 96
Resolved with sequelae
Dose not changed
Related
Dose reduced
Related
4208/004
73/Female
Oesophageal infection (Grade 3)
SD 52
Resolved
Dose not changed
Related
4307/004
59/Female
White
Pneumonia (Grade 3)
SD 825
Resolved
Not applicable
Related
4404/003
57/Male
White/ Italy
Non-small cell lung cancer
metastatic
Herpes Zoster (Grade 3)
SD 888
Resolved
Spontaneous bacterial peritonitis
(Grade 3)
SD 888
Resolved
Drug interrupted
Not related
Drug interrupted
Not related
4404/011
71/Male
White/ Italy
Non-small cell lung cancer
metastatic
Q fever (Grade 3)
SD 406
Resolved
Pneumonia (Grade 3)
SD 636
Not resolved
Drug interrupted
Not related
Drug interrupted
Not related
4406/003
53/Male
White/ Italy
Non-small cell lung cancer
metastatic
Urinary tract infection (Grade 3)
SD 568
Resolving
Dose not changed
Not related

70
Drug Safety Report No: 1132062
Patient number
Age/Sex
Ethnicity/Country
Indication
MedDRA PT (Grading)
Time to Event Onset (in days)
Outcome
Action taken with Pralsetinib
Causality (as per
investigator)
4410/008
65/Male
White/Italy
Non-small cell lung cancer
metastatic
Pneumonia legionella (Grade 3)
SD 26
Resolved with sequelae
Pneumonia (Grade 3)
SD 58
Not resolved
Drug interrupted
Not related
Drug interrupted
Not related
4508/002
79/Female
White
Infection (Grade 3)
SD 89
Resolving
Dose not changed
Not related
4517/001
58/Male
White
Urinary tract infection (Grade 3)
SD 1001
Resolved
Bronchopulmonary aspergillosis
(Grade 3)
SD 148
Resolved
Dose not changed
Not related
Dose not changed
Not related
4601/001
61/Female
White/Switzerland
Non-small cell lung cancer
metastatic
Pneumonia (Grade 3)
SD 568
Resolved
Dose not changed
Not related
4601/003
68/Female
White/Switzerland
Non-small cell lung cancer
metastatic
Herpes Zoster (Grade 3)
SD 32
Resolved
Dose not changed
Not related
4801/002
54/Female
White/ United Kingdom
Non-small cell lung cancer
metastatic
Pneumocystis jirovecii pneumonia
(Grade 3)
SD 55
Resolved
Dose reduced
Related
7301/006
64/Male
American Indian or Alaska
Native
Oesophageal candidiasis (Grade
3)
SD 280
Resolved
Pneumonia (Grade 3)
SD 368
Resolved
Dose not changed
Not related
Dose not changed
Related

71
Drug Safety Report No: 1132062
Patient number
Age/Sex
Ethnicity/Country
Indication
MedDRA PT (Grading)
Time to Event Onset (in days)
Outcome
Action taken with Pralsetinib
Causality (as per
investigator)
4404/005
53/Male
White/ Italy
Non-small cell lung cancer
metastatic
Device related infection (Grade 4)
SD 20
Resolved
Drug Interrupted
Not related
4703/002
51/Female
Unknown/ United Kingdom
Non-small cell lung cancer
metastatic
Sepsis (Grade 4)
SD 41
Not resolved
Dose not changed
Not related
7301/012
65/ Female
American Indian or Alaska
Native/ Mexico
Non-small cell lung cancer
metastatic
Urosepsis (Grade 4)
SD 35
Not resolved
Drug Interrupted
Related
8411/001
Japan
Non-small cell lung cancer
metastatic
Pneumocystis jirovecii pneumonia
(Grade 4)
SD 66
Resolved
Drug withdrawn
Related
MedDRA Version 27.0. SD: Study Day
Clinical Output Source:
root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/l_ae_INVI
NF_SE.out

72
Drug Safety Report No: 1132062
Appendix 3
Overview of Grade 3-5 Infection AEs by MedDRA PT in
ARROW Study
The below Table (continued from Table 11) summarizes the Grade 3-5 infection AEs by
MedDRA PT which were observed in ARROW study. The below mentioned AEs
reported a frequency of ï€¼1%.
MedDRA PT
Total Number of Patients (N=590)
Grade 3 AE (%)
Grade 4 AE (%)
Grade 5* AE (%)
Total* (%)
Patients with
SAEs
125 (21.2)
19 (3.2)
24 (4.1))
183 (31.0)
Bacteraemia
3 ( ï€¼1)
0
0
5 ( ï€¼1)
Appendicitis
4 ( ï€¼1)
0
0
4 ( ï€¼1)
Cellulitis
3 ( ï€¼1)
0
0
4 ( ï€¼1)
Clostridium
difficile colitis
4 ( ï€¼1)
0
0
4 ( ï€¼1)
Pyelonephritis
4 ( ï€¼1)
0
0
4 ( ï€¼1)
Urosepsis
1 ( ï€¼1)
2 ( ï€¼1)
1 ( ï€¼1)
4 ( ï€¼1)
Gastroenteritis
2 ( ï€¼1)
0
0
3 ( ï€¼1)
Herpes zoster
3 ( ï€¼1)
0
0
3 ( ï€¼1)
Lung infection
3 ( ï€¼1)
0
0
3 ( ï€¼1)
Pneumonia
influenzal
1 ( ï€¼1)
0
0
3 ( ï€¼1)
Upper respiratory
tract infection
2 ( ï€¼1)
0
0
3 ( ï€¼1)
Urinary tract
infection bacterial
3 ( ï€¼1)
0
0
3 ( ï€¼1)
Escherichia
sepsis
2 ( ï€¼1)
0
0
2 ( ï€¼1)
Escherichia
urinary tract
infection
0
0
0
2 ( ï€¼1)
Hepatitis B
2 ( ï€¼1)
0
0
2 ( ï€¼1)
Lymph node
tuberculosis
1 ( ï€¼1)
0
0
2 ( ï€¼1)
Pneumonia
legionella
2 ( ï€¼1)
0
0
2 ( ï€¼1)
Pneumonia
staphylococcal
2 ( ï€¼1)
0
0
2 ( ï€¼1)
Pneumonia viral
1 ( ï€¼1)
1 ( ï€¼1)
0
2 ( ï€¼1)
Respiratory tract
infection
2 ( ï€¼1)
0
0
2 ( ï€¼1)

73
Drug Safety Report No: 1132062
MedDRA PT
Total Number of Patients (N=590)
Grade 3 AE (%)
Grade 4 AE (%)
Grade 5* AE (%)
Total* (%)
Septic shock
0
2 ( ï€¼1)
0
2 ( ï€¼1)
Skin infection
1 ( ï€¼1)
0
0
2 ( ï€¼1)
Abdominal
infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Appendicitis
perforated
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Arthritis bacterial
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Arthritis infective
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Atypical
mycobacterial
pneumonia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Bronchitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Bronchitis
bacterial
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Bronchopulmonar
y aspergillosis
0
0
0
1 ( ï€¼1)
Cellulitis of male
external genital
organ
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Cholecystitis
infective
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Cystitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Device related
infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Empyema
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Enterobacter
bacteraemia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Enterococcal
bacteraemia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Epididymitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Escherichia
bacteraemia
0
0
0
1 ( ï€¼1)
Infectious colitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Influenza
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Kidney infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Klebsiella
bacteraemia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Lower respiratory
tract infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Meningitis
0
0
1 ( ï€¼1)
1 ( ï€¼1)

74
Drug Safety Report No: 1132062
MedDRA PT
Total Number of Patients (N=590)
Grade 3 AE (%)
Grade 4 AE (%)
Grade 5* AE (%)
Total* (%)
Meningitis
enterococcal
0
1 ( ï€¼1)
0
1 ( ï€¼1)
Neutropenic
sepsis
0
1 ( ï€¼1)
0
1 ( ï€¼1)
Oropharyngeal
candidiasis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Osteomyelitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Pancreatic
abscess
0
1 ( ï€¼1)
0
1 ( ï€¼1)
Pleural infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Pneumonia
bacterial
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Pneumonia
cytomegaloviral
0
0
1 ( ï€¼1)
1 ( ï€¼1)
Pneumonia
haemophilus
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Proteus infection
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Pseudomembran
ous colitis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Psoas abscess
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Pyelonephritis
acute
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Renal
tuberculosis
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Septic arthritis
staphylococcal
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Sinusitis
aspergillus
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Sinusitis bacterial
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Staphylococcal
bacteraemia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
Streptococcal
bacteraemia
1 ( ï€¼1)
0
0
1 ( ï€¼1)
This total count also takes into account AEs of Grade 1 and Grade 2 severity.
MedDRA Version: 19.1
Source Output: Table 14.3.2.8.1.11 in Clinical Study Report 1113097 for ARROW Study

75
Drug Safety Report No: 1132062
Appendix 4
Summaries of the Cases Reporting Grade 5 Infections from
the Company Safety Database (N=77)

Category B (N=38)
AER
Number
Age (in
Years)
Sex
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset
(in days)
Drug Type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Narrative
MAH Comment
2858632
57
Not
reported
ITALY
Non-
Interventio
nal
Study/Pro
gram
Healthcar
e
profession
al
Pneumonia

Sepsis
Grade 5

Grade 5
92

NR
(1) PRALSETINIB (S)

(2) RAMIPRIL (C)

(3) ZOLEDRONIC ACID
(C)

(4) CISPLATIN (C)

(5) PEMETREXED (C)

(6) OXYGEN (T)

(7) CEFTRIAXONE
SODIUM (T)
Dose interrupted

Dose interrupted
N/A

N/A
N/A

N/A
Fatal

Fatal
"AER 2858632 (PT: Pneumonia, Sepsis)

This non-interventional study case concerned a 57-year-old
patient (sex unspecified) from Italy who developed pneumonia
and sepsis while receiving treatment with pralsetinib for non-
small cell lung cancer and lung neoplasm malignant. The
patientâ€™s medical history and past drugs were not reported.
Concurrent conditions included bone metastasis. Concomitant
medications included ramipril, zoledronic acid, cisplatin and
pemetrexed. Maternal family history included myocardial
infarction.

After 29 days of starting treatment with pralsetinib (400 mg
daily), the patient developed hypertension. An unspecified
duration later, the pralsetinib dose was reduced to 300 mg daily.
After 92 days of starting treatment with pralsetinib, the patient
developed pneumonia and fever. The next day, the patient was
hospitalized due to persistent fever and dyspnea. Upon
admission, the patientâ€™s temperature was 37.2Â°C and oxygen
saturation was critically low at 69%. Initial CT scan confirmed the
diagnosis of pneumonia. A CT scan without contrast detected
extensive parenchymal blob in the lower right lobe and
significant left pleural effusion. The treatment regimen included
oxygen therapy with continuous positive airway pressure,
steroids, ceftriaxone and left pleural drainage. A follow-up CT
scan showed no pulmonary embolism. Blood tests indicated
severe sepsis, likely secondary to pneumonia, with markedly
elevated procalcitonin, C-reactive protein and creatinine levels.
After 92 days of starting treatment with pralsetinib, the patient
died due to pneumonia and sepsis. An autopsy was not
performed. The physician did not report the causality between
fatal pneumonia and fatal sepsis with pralsetinib."

AER
Number
Age (in
Years)
Sex
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset
(in days)
Drug Type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Narrative
MAH Comment


Though the patient developed pneumonia and sepsis while
being treated with pralsetinib, the events could be explained the
immunocompromised state due to the progression of underlying
malignancy and the co-administration of medications like
cisplatin and pemetrexed.
3018085
70
Male
TURKIYE
Non-
Interventio
nal
Study/Pro
gram
Healthcar
e
profession
al
COVID-19
Grade 5
41
(1) PRALSETINIB (S)
NR
Unkown
N/A
Fatal
"AER 3018085 (PT: COVID-19)

This non-interventional study case concerned a 70-year-old male
from Turkey who developed COVID-19, 41 days after starting
treatment with pralsetinib for non-small cell lung cancer. The
patient's medical history, concomitant medications or past drugs
were not reported. Concurrent conditions include hypertension,
benign prostatic hyperplasia and bronchial asthma. After 41 days
of starting treatment with pralsetinib, the patient was tested
positive for COVID 19 and was hospitalized due to respiratory
distress associated with COVID-19. After 77 days of starting
treatment with pralsetinib, the patient died due to COVID-19. It
was not reported if an autopsy was performed. The physician
assessed the COVID-19 as not related to pralsetinib."


Though the patient devloped COVID 19 41 days after starting
pralsetinib, the occurence of event could be explained by the
elderly age and concurrent condition of bronchial asthama
3065813
64
Female
ITALY
Non-
Interventio
nal
Study/Pro
Sepsis

Abdominal
abscess


Grade 5
NR

NR
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE
SODIUM (S)

(3) BISOPROLOL (S)

(4) FUROSEMIDE (S)
N/A

N/A
N/A

N/A
N/A

This spontaneous case concerns a 64-year-old female patient
who developed sepsis and abdominal abscess, unspecified
duration after initiating therapy with pralsetinib for thyroid cancer.
Concomitant medications included pantoprazole, however no
past medical history, past drugs, concurrent conditions were
reported. After an unspecified duration, the patient developed
sepsis for which the patient was hospitalized. Reportedly, the
patient developed abdominal abscess which was likely to be a

AER
Number
Age (in
Years)
Sex
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset
(in days)
Drug Type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Narrative
MAH Comment
gram
Healthcar
e
profession
al

NR

(5)
METHYLPREDNISOLONE
(S)

(6) APIXABAN (S)

(7) PANTOPRAZOLE
SODIUM
SESQUIHYDRATE (C)
N/A
Fatal

Not Reported
complication of pancreatic resection surgery. After approximately
```